Studie: Arrowhead Research Corp. - Der Joker unter den Nanotechs - 500 Beiträge pro Seite

[NOBODY_III]

http://www.financial.de/pdf/midas/CR_ARWR_D_120105.pdf

Quelle: financial.de

Kennt jemand diesen Wert? Was ist von der Studie zu halten?

[NOBODY_III]

Das haben diese 20 seitigen Studien so an sich. Niemand liest sie bis zum Ende durch.

Deshalb wohl auch keine Kommentare.

[NOBODY_III]

Börse Symbol Währ. Vortag akt.Kurs Diff. % Handelsvol. gehand. St. Kurszeit
Nasdaq ARWR USD 3,89 4,02 + 0,130 + 3,34 % 111.205 28.009 12. Jan 22:01
Berlin HDP EUR 3,30 3,14 - 0,160 - 4,85 % 36.463 11.400 12. Jan 17:45

Der Kurs von 3,14 € in Berlin ist immer noch zu hoch.
4,02 USD entsprechen 3,06613 €.

[suncomesout]

Ergo: Bis 15:30 Uhr warten und drüben einsammeln!
Nanotechnologie mit Zukunft!

SCO

[Paepstin]

Sun ist eine Vorwitznase!

Du sollst doch nicht alles verraten!
Päpstin

Ich habe noch nicht alles gelesen, Mensch, sieht aber echt gut aus! Endlich mal was für ein längerfristiges Investment, wie mir scheint!

[NOBODY_III]

Paepstin ist gut! Muß man auch erstmal drauf kommen.

[Kostolanys Erbe]

hi leute,

habe mir auch die studie durchgelesen. aktueller kurs heute von arwr 4 dollar.
vorweg möchte ich nur sagen, das ich " nicht " in ARWR investiert bin.
war in anderen nanowerten drin und bin noch in mfic investiert.

bei diesen internationalen werten hat midas ein research gemacht:

www.midasresearch.de

Research

ANALYSEN ZU INTERNATIONALEN AKTIEN

Hier finden Sie ResearchFlashes und Studien zu internationalen Gesellschaften, die in der Regel über ein Zweit-Listing an einer deutschen Börse verfügen


Studie ARROWHEAD RESEARCH CORP. (USA), Veröffentlichungsdatum 12.01.2005, (PDF 791528 Bytes)

Studie EPITAN LTD. (AUS), Veröffentlichungsdatum 27.10.2004, (PDF 871786 Bytes)

Studie CALLISTO PHARMACEUTICALS INC. (USA), Veröffentlichungsdatum 13.10.2004, (PDF 407079 Bytes)

Studie PINNACLE RESOURCES INC. (USA), Veröffentlichungsdatum 28.09.2004, (PDF 683585 Bytes)

Studie MIRANDA GOLD CORP. (CAN), Veröffentlichungsdatum 22.09.2004, (PDF 867270 Bytes)

Company Profile AQUA-SOCIETY INC (USA), Veröffentlichungsdatum 14.09.2004, (PDF 1776166 Bytes)

Company Profile EPITAN LTD (AUS), Veröffentlichungsdatum 03.09.2004, (PDF 353933 Bytes)

Studie BODISEN BIOTECH INC. (USA/China), Veröffentlichungsdatum 03.08.2004, (PDF 367507 Bytes)

Studie DIATECT INT. CORP. (USA), Veröffentlichungsdatum 29.07.2004, (PDF 402031 Bytes)

Studie DIGITALROOSTER.COM LTD (KAN), Veröffentlichungsdatum 27.07.2004, (PDF 442008 Bytes)

Studie ULTRAGUARD WATER SYSTEMS CORP (KAN), Veröffentlichungsdatum 16.07.2004, (PDF 381633 Bytes)

Kompendium Exploration & Mining, Veröffentlichungsdatum 13.07.2004, (PDF 2719872 Bytes)

Studie GLOBETECH VENTURES CORP (KAN), Veröffentlichungsdatum 13.07.2004, (PDF 618870 Bytes)

Studie EAGLECREST EXPLORATIONS LTD (KAN), Veröffentlichungsdatum 13.07.2004, (PDF 444885 Bytes)

Studie TERRA NOVA GOLD CORP (KAN), Veröffentlichungsdatum 13.07.2004, (PDF 658410 Bytes)

Studie USCORP (USA), Veröffentlichungsdatum 13.07.2004, (PDF 874410 Bytes)

Studie SILVERADO GOLD MINES LTD (USA), Veröffentlichungsdatum 13.07.2004, (PDF 378406 Bytes)

Studie ABERDENE MINES (USA), Veröffentlichungsdatum 02.07.2004, (PDF 978132 Bytes)

Studie ISOTIS ORTHOBIOLOGICS S.A. (CH), Veröffentlichungsdatum 29.06.2004, (PDF 423678 Bytes)

Studie TELECOMMUNICATION PRODUCTS (USA), Veröffentlichungsdatum 25.06.2004, (PDF 365131 Bytes)

Studie PSIVIDA LTD (AUS), Veröffentlichungsdatum 24.06.2004, (PDF 602740 Bytes)

Studie SUN NETWORK GROUP (USA), Veröffentlichungsdatum 21.06.2004, (PDF 368856 Bytes)

Update CEL-SCI Corp. (USA) (ASCO Publikation), Veröffentlichungsdatum 11.06.2004, (PDF 361183 Bytes)

Update EAGLECREST EXPLORATIONS (KAN), Veröffentlichungsdatum 24.05.2004, (PDF 436950 Bytes)

Update TELEPLUS Enterprises (KAN) (SmartCell Übernahme), Veröffentlichungsdatum 27.04.2004, (PDF 337545 Bytes)

Studie ALTAIR Nanotechnologies Inc. (USA), Veröffentlichungsdatum 20.04.2004, (PDF 379138 Bytes)

Studie CEL-SCI Corp. (USA), Veröffentlichungsdatum 29.03.2004, (PDF 772895 Bytes)

Studie TELEPLUS Enterprises (KAN), Veröffentlichungsdatum 26.03.2004, (PDF 774013 Bytes)

Studie PHYTOPHARM (UK), Veröffentlichungsdatum 23.03.2004, (PDF 363849 Bytes)

Studie MT ULTIMATE HEALTHCARE (USA), Veröffentlichungsdatum 23.03.2004, (PDF 351256 Bytes)

Studie THE EXPERIENTIAL AGENCY (USA), Veröffentlichungsdatum 19.03.2004, (PDF 349686 Bytes)

Update T & G 2 (USA) (Abschluss Kreditfacilität), Veröffentlichungsdatum 21.01.2004, (PDF 361868 Bytes)

Studie T & G 2 (USA), Veröffentlichungsdatum 05.11.2003, (PDF 643559 Bytes)

Update SILVERADO GOLD MINES (USA), Veröffentlichungsdatum 15.10.2003, (PDF 968358 Bytes)

Studie MELKIOR RESOURCES (CAN), Veröffentlichungsdatum 15.10.2003, (PDF 435805 Bytes)

Studie CALLISTO PHARMACEUTICALS (USA), Veröffentlichungsdatum 26.08.2003, (PDF 459372 Bytes)

Studie RESPONSE BIOMEDICAL (CAN), Veröffentlichungsdatum 25.08.2003, (PDF 428361 Bytes)

Studie EAGLECREST EXPLORATIONS (CAN), Veröffentlichungsdatum 21.08.2003, (PDF 512819 Bytes)

Studie NEW SHOSHONI VENTURES (CAN), Veröffentlichungsdatum 11.06.2003, (PDF 910845 Bytes)

Studie LEISURE CANADA (CAN), Veröffentlichungsdatum 21.05.2003, (PDF 464733 Bytes)

Studie SILVERADO GOLD MINES (USA), Veröffentlichungsdatum 19.05.2003, (PDF 498089 Bytes)

Studie IMMTECH INTERNATIONAL (USA), Veröffentlichungsdatum 26.03.2003, (PDF 418548 Bytes)

hier zu deutschen werten:
Research

ANALYSEN ZU DEUTSCHEN AKTIEN

Hier finden Sie ResearchFlashes und Studien zu Unternehmen, die ihr primäres Listing an einer deutschen Börse haben


Update TRIA IT-SOLUTIONS AG, Veröffentlichungsdatum 05.01.2005, (PDF 333129 Bytes)

Update UNITED INTERNET (Q3/04 Bericht), Veröffentlichungsdatum 19.11.2004, (PDF 400799 Bytes)

Studie HELIAD EQUITY PARTNERS, Veröffentlichungsdatum 17.11.2004, (PDF 732368 Bytes)

Studie TRIA IT-SOLUTIONS AG, Veröffentlichungsdatum 22.10.2004, (PDF 652826 Bytes)

Flash MORPHOSYS (MOR202 Daten), Veröffentlichungsdatum 20.10.2004, (PDF 362981 Bytes)

Update UNITED INTERNET (Q2/04 Bericht), Veröffentlichungsdatum 30.08.2004, (PDF 385638 Bytes)

Flash MORPHOSYS (Q2/04 Bericht), Veröffentlichungsdatum 30.07.2004, (PDF 365022 Bytes)

Interview MATCHNET, Veröffentlichungsdatum 09.06.2004, (PDF 105574 Bytes)

Kurzstudie UNITED INTERNET, Veröffentlichungsdatum 02.06.2004, (PDF 387163 Bytes)

Interview WAPME SYSTEMS (Q1/04 Bericht), Veröffentlichungsdatum 01.06.2004, (PDF 108373 Bytes)

Flash MORPHOSYS (Kooperationsvereinbarung mit Novartis), Veröffentlichungsdatum 24.05.2004, (PDF 365952 Bytes)

Update TRIA IT-solutions, Veröffentlichungsdatum 04.05.2004, (PDF 348346 Bytes)

Flash MORPHOSYS (Q1/04 Bericht), Veröffentlichungsdatum 30.04.2004, (PDF 358343 Bytes)

Kurzstudie MOBILCOM, Veröffentlichungsdatum 21.04.2004, (PDF 357717 Bytes)

Interview SILTRONIC IPO, Veröffentlichungsdatum 22.03.2004, (PDF 120620 Bytes)

Update MORPHOSYS (Hochstufung nach Analyse der Ergebnisse 2003), Veröffentlichungsdatum 03.03.2004, (PDF 373824 Bytes)

Interview MANNHEIMER (a.o.HV), Veröffentlichungsdatum 25.02.2004, (PDF 107054 Bytes)

Flash MORPHOSYS (Vorläufige Ergebnisse 2003), Veröffentlichungsdatum 11.02.2004, (PDF 355586 Bytes)

Flash MORPHOSYS (Kooperationsvereinbarung mit Pfizer), Veröffentlichungsdatum 29.12.2003, (PDF 356651 Bytes)

Kurzstudie IDS Scheer, Veröffentlichungsdatum 19.12.2003, (PDF 370171 Bytes)

Kurzstudie ADVA Optical, Veröffentlichungsdatum 15.12.2003, (PDF 360545 Bytes)

Flash MORPHOSYS (Daten zum Alzheimerprojekt mit Roche), Veröffentlichungsdatum 05.12.2003, (PDF 358809 Bytes)

Update MORPHOSYS (Q3/03 Bericht), Veröffentlichungsdatum 30.10.2003, (PDF 378375 Bytes)

Interview TRIA IT-SOLUTIONS (Wandelanleihe), Veröffentlichungsdatum 14.10.2003, (PDF 104501 Bytes)

Flash MORPHOSYS (Präklinische Daten), Veröffentlichungsdatum 10.10.2003, (PDF 363923 Bytes)

Update EVOTEC OAI (Q2/03 Bericht), Veröffentlichungsdatum 14.08.2003, (PDF 365438 Bytes)

Flash MORPHOSYS (News zu Meilenstein mit Centocor Inc.), Veröffentlichungsdatum 01.08.2003, (PDF 378207 Bytes)

Update MORPHOSYS (Q2/03 Bericht), Veröffentlichungsdatum 31.07.2003, (PDF 367917 Bytes)

Flash EVOTEC OAI (Q1/03 Bericht), Veröffentlichungsdatum 26.06.2003, (PDF 373043 Bytes)

Flash MORPHOSYS (Q1/03 Bericht), Veröffentlichungsdatum 07.05.2003, (PDF 346171 Bytes)

Studie INFINEON, Veröffentlichungsdatum 19.03.2003, (PDF 376300 Bytes)


was haltet ihr davon?

kosto

[NOBODY_III]

Kostolanys Erbe

Du schreibst:

habe mir auch die studie durchgelesen. aktueller kurs heute von arwr 4 dollar.
vorweg möchte ich nur sagen, das ich " nicht " in ARWR investiert bin.
war in anderen nanowerten drin und bin noch in mfic investiert.

Eigentlich sollte man doch erwarten, daß jemand, der eine 20 seitige Studie durchliest, auch eine Einschätzung abgibt. In Abwandlung eines Sprichwortes könnte man deswegen vermuten:

Keine Einschätzung ist auch eine Einschätzung.
Also Finger davon?

Die Auflistung der anderen Studien von midasresearch sagt doch nichts über die Bewertung von ARWR aus. Oder?

Börse Symbol Währ. Vortag akt.Kurs Diff. % Handelsvol. gehand. St. Kurszeit
Nasdaq ARWR USD 4,02 4,00 - 0,020 - 0,50 % 76.882 29.930 13. Jan 22:01
Berlin HDP EUR 3,15 3,15 + 0,000 + 0,00 % 22.937 7.007 13. Jan 19:39

4,00 USD entsprechen 3,01614 €

Leider sagt die o.a. Statistik von WO wenig aus.

Lt. Consors ergaben sich folgende Nasdaq-Schlußkurse:

Bid 3,50 500
Letzter Umsatz 300 Tagesumsatz 44.000
Ask 4,01 1.500

Für meinen Geschmack ist der Spread zwischen Bid und Ask zu groß.

Der Ask-Kurs kann also ein Mond-Kurs sein, und selbst dieser ergibt umgerechnet nur 3,016 €.

In Berlin schwankten die Kurse zwischen 3,40 und 3,15 €.
Die Aktie schloß damit auf dem Tagestief von 3,15 €.

Da die meisten eine 20 seitige Studie ohnehin nicht lesen oder bestenfalls nur überfliegen, hier noch eine kürzere Info:



Arrowhead: Spekulativer Kauf (Midas Research)
Aktien & Co


In einer Studie vom 12. Januar bewerten die Analysten von Midas Resarch die Aktie des amerikanischen Industriekonzerns Arrowhead Research Corp. mit "Spekulativer Kauf". Das Kursziel liegt bei 6 Dollar.
Mit Arrowhead Research erhalte der Anleger eine Art Optionsschein auf die Nanotechnolgie. Aktuell sei zwar noch nicht genau absehbar, wann Arrowhead signifikante Umsätze und Erträge realisieren werde, das Unternehmen sei jedoch durch sein Patentportfolio so breit aufgestellt, dass die Analysten ihm deutlich größere Erfolgsaussichten bemessen als den vielen Nanotech-Unternehmen mit einem eher engen Technologie- bzw. Produktfokus. Eine Börsenbewertung von Arrowhead mit 100 Mio. bis 150 Mio. Dollar halten die Analysten nicht für unrealistisch. Dies würde bei der gegenwärtigen Aktienanzahl von 13.625.546 einer Bandbreite für den Kurs von 7,35 bis 11,0 Dollar entsprechen.

Wie bei einem Optionsschein sei auch bei Aktien aus dem Nanotech-Bereich mit erhöhter Kursvolatilität zu rechnen. Allerdings sollte eine Anlage in Arrowhead Aktien über den technologischen Fortschritt mit der Zeit an Wert gewinnen und nicht wie ein Optionsschein an Zeitwert verlieren. Wenn die Gesellschaft darüber hinaus fortfahre, mit positiven Meldungen auf sich aufmerksam zu machen - wie in den letzten Wochen bereits geschehen -, erwarten die Analysten, dass der Aktienkurs das Kursziel von 6 Dollar sogar wesentlich schneller erreichen könne.

Analyst: Midas Research
Rating des Analysten: Spekulativer Kauf


Quelle: Aktien & Co 13.01.2005 14:42:00


Die Anleger mögen sich ihr eigenes Urteil bilden, möglichst die Studie komplett durchlesen, bevor sie einen Kauf erwägen.

Insofern dient dieser Thread auch nur dem Gedankenaustausch und stellt keinesfalls eine Kaufempfehlung dar.


Gruß

Nobody

[Paepstin]

Mahlzeit!
Ich habe einmal versucht, mir ein Bild zu machen!
Arrowhead Research Corp. scheint sehr gut diversifiziert im Nanobereich aufgestellt zu sein.

Unternehmen Börsenkürzel Anzahl der Patente max. % der Patente in
einer Unterklasse
Arrowhead ARWR 32 9%
Quantum Dot privat 27 22%
Nanosys privat 58 29%
Nanogen NGEN 86 35%
NVE NVEC 32 44%
Nano-Proprietary NNPP.OTC 68 47%
Nantero privat 6 50%
Nanolink privat 26 62%
Nanosphere privat 21 76%
Carbon Nanotechnologies privat 10 100%
Quelle: CHI-Research; MIDAS Research

Arrowhead verfügte zum 30.09.2004 über liquide Mittel in Höhe von USD 8,55 Mio. Die Verbindlichkeiten betrugen USD 689.698. Das Eigenkapital lag bei USD 9,45 Mio. und machte bei einer Bilanzsumme von USD 11,915 Mio. eine Eigenkapitalquote von 79,3% aus.

Dem stehen Finanzierungsverpflichtungen von rund USD 26,0 Mio. in den nächsten zwei Jahren entgegen!

Schlüsselpatente von Arrowhead in Nanoelektronik, Nanobio und Ferroelektrische Nanomaterialien sichern jedoch nach meinem Ermessen enorme Zuschüsse für weitere Forschung und Entwicklung - und wenn nur ein kleiner Teilbereich den Durchbruch schafft, dann geht die Rechnung auf.

Soweit ich das hier beurteilen kann, ein interessantes und vielversprechendes Investment.
Ich habe mit einer kleinen Position angefangen und beobachte die weitere Entwicklung.

Päpstin

[Paepstin]

Das hat Nobody-III gut ausgegraben!
Und so jungfräulich hier in WO!

Päpstin

[Kostolanys Erbe]

hi nobody III,

ich habe keine einschätzung abgegeben, weil ich mich bisher nicht mit dem unternehmen beschäftigt habe.
habe bisher nur die studie gelesen.

sicherlich ist eine investition in arwr eine chance frühzeitig an die weitere entwicklung bei arwr teizuhaben.

das arwr in der forschung steckt und verluste erwirtschaftet stört mich gar nicht (das machen die anderen unternehmen auch), was auch sicherlich nachholpotential gegenüber den anderen unternehmen rechtfertigt oder die anderen müssten im kurs her fallen.

jedoch was mich ein bischen skeptisch macht ist die finanzierungsgrundlage bzw. die aktienoptionen von arwr.
arwr ist berechtigt bis zu 50.000.000 stammaktien und bis zu 20.000.000 vz-aktien zu emittieren. zum 30.09.04 waren davon 13.631.546 stammaktien ausgegeben. weitere 13.837.748 aktien sind für die ausübung von ausstehenden aktien-optionsscheinen reserviert sowie 3.000.000 aktien für arwr 2000er aktienoptionsplan. auf der hv am 20.01.05 will arwr die zustimmung holen, bis zu 75.000.000 aktien bestehend aus 70.000.000 stammaktien und 5.000.000 vz-aktien auszugeben.
dann seite 16 unten die 13 millionen os berechtigen den inhaber die aktie zu 1,5 dollar erwerben.....nicht so klasse!!

daher warte ich erstmal den 20.01.05 ab.
setze arwr auf die watchlist

kosto

[NOBODY_III]

Das ist doch mal ein Wort!

[diwi0815]

Hallo@
ich habe auch die Midas-Studie gelesen. Allerdings tue ich mich immer ein wenig schwer mit gekauften Analysen. Midas könnte da in einen Interessenskonflikt kommen, wenn die Analyse negativ ausfallen würde.

So stöberte ich heute morgen im Netz, um ein paar weitere Infos zu bekommen:

19.10.04:
Insert will be filing an Investigational New Drug application with the US Food and Drug Administration. Upon clearance of regulatory requirements, Insert will sponsor an open-label, dose-escalation Phase I study in patients with unresectable or metastatic solid tumors. Based on results from the Phase I study, Insert plans to follow up with a disease-specific Phase II study also at the City of Hope.
Discovered in the 1960s, camptothecin is a naturally occurring, water-insoluble alkaloid that has established potent activity against a broad spectrum of cancer types. While analogues of camptothecin (e.g., irinotecan and topotecan) continue to realize nearly $1 billion of annual sales worldwide, to date, camptothecin has not been commercialized due to its poor solubility and its unfavorable pharmacokinetics/pharmacodynamics. Recent animal studies conducted by Insert demonstrated that treatments with camptothecin using the Cyclosert(TM) delivery system resulted in protracted reduction and/or elimination of tumors. Further, the tests showed that the reoccurrence of tumors after treatment was much less than other treatment groups, including irinotecan.

Wenn der Krebs nicht nur aufgehalten, sondern auch eliminiert werden kann, waere das natuerlich ein Hit, gerade auch im Vergleich zu den anderen Chemotherapeutika. Aber wie ist das bei den Studien? Jede Phase filtert 9 von 10 Medikamenten raus und nur eines erreicht die nächste Phase. Bis zur Zulassung ist es noch ein weiter Weg. Auch zeitlich. So ein Transportsystem halte ich fuer sehr interessant. Viele Medikamente kommen trotz Wirksamkeit nicht auf den Markt, weil die Resorption schlecht ist - kein Patient mag sich täglich in die Venen spritzen - oder die Nebenwirkungen zu stark sind.

16.12.04 Jahresbericht:
Because we are a developmental stage company, there are few objective metrics by which our progress may be measured. Consequently, we expect that the market price of our Common Stock will likely continue to fluctuate significantly. We do not expect to generate substantial revenue for several years from the license or sale of our nanotechnology, if at all.

Letztlich entscheidend ist, ob und ab wann Geld verdient wird. Die Geschaeftsleitung selber sagt, dass noch einige Jahre ins Land ziehen werden, bis es soweit ist. Die Frage ist nun, ob Arrowhead bis dahin ueberleben kann. Das hängt wohl vom Kapitalmarkt ab. Deshalb ist es interessant, zu sehen, wie der Markt die anstehenden Finanzierungen aufnimmt (Kapitalbedarf in den nächsten 2 Jahren ca 26Mio USD). Sollte das mit Cyclosert und Campothecin was werden, könnte man schon ab Phase II Milestonezahlungen von einem möglichen Vertriebspartner bekommen.

Unter: http://www.nasdaq.com/asp/Holdings.asp?symbol=ARWR&selected=…
bekommt man Insidertrades aufgelistet. In den letzen 3 Monaten wurden 6 Verkäufe getätigt. Der letzte von MCKENNEY, CHARLES am 10.1.05.

Unter: http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000…
erhält man die überaus positive Einschätzung von CHI über die Patente von Arrow Research.

Mir erscheint dieser Wert wirklich sehr interessant zu sein! Was mich irritiert sind die Insiderverkäufe. ARWR ist auf meiner Watchliste. Da standen schon einige Werte die kräftig gestiegen sind
Nur leider habe ich diese nie gekauft
Gruß diwi

[suncomesout]

@diwi0815

Schön gefunden!

Nur: der letzte Insidertrade der stattgefunden hat, bestand im Einlösen von Kaufoptionen zu 1$ durch McKenny am 10.1.05.und NICHT im Verkauf:
ARWR ARWR
Arrowhead Research Corporation NASDAQ-SCM


Insider Trades of MCKENNEY, CHARLES Description
Traded Price Holdings
ARROWHEAD RESH CORP DIR 01/10/2005 Form 4 Option OE D 25,000 $1.000 25,200

... Und der wird schon wissen, warum

SCO

[diwi0815]

@SCO

ups! Ein kleiner aber feiner Unterschied! Danke fürs Richtigstellen.

diwi

[Paepstin]

Super sun,

dass du mal genauer hingeschaut hast! So sieht doch die ganze Geschichte schon anders aus!

Päpstin

[krauT1]

Arrowhead im aktionär no.4

sie bewerten die aktie als "unglaublich günstig"

die aktuelle börsenbewertung gibt nur einen bruchteil des wahren protenzials an.

Ziel: 6,50 Stopp: 2,50

Marktkapital: 54,8 Mio.$
Ums.05e 2,6 Mio.$

[NOBODY_III]

Dann taucht die Aktie wohl demnächst in diversen DAC-Fonds auf, und Markus Frick dürfte vielleicht auch noch unterstützend eingreifen.

[Paepstin]

Eigentlich wollte ich schon noch ein wenig mehr Zeit, um zu recherchieren und mich einzudecken!
Aber bitte, der Aktionär bringt erst mal ordentliche Schwankungen rein und warum nicht mal bisschen traden mit der ersten Postion?

Päpstin

[Paepstin]

Steigt

[Paepstin]

Guten Morgen,

die 21 sind hier mal nötig, damit man nicht ständig zurück scrollen muss!

Auf gehts in einen neuen Tag!

Päpstin

[umbertoni]

Ich meine, in einer Studie von Adiuventa gelesen zu haben, dass Arrowhead noch in einer gaaaaaaaaanz frühen Pahse ist, selbst für einen Nanotechwert noch früh!

[NOBODY_III]

Parkettgeflüster: Arrowhead zieht an

(Börse Berlin-Bremen) Reges Interesse zogen am Mittwoch ausgewählte HotStocks auf sich.

Mit einem Kursplus von 25 Prozent fielen in Berlin wieder Bougainville Copper (WKN: 852 652) auf. Dieses australische Unternehmen erforscht und baut Gold-, Silber- und Kupfervorkommen ab. Der Abbau findet auf der Insel Bouganville auf Papua Neuguinea statt. Wie bereits erwähnt, brachte offenbar eine Studie von Global Profit Hunter Phantasie in diesen Wert.

Arrowhead (WKN: A0CA96) verteuert sich von 3,15 auf 3,23 Euro. In einer Studie vom 12. Januar bewerteten die Analysten von Midas Research die Aktie des amerikanischen Industriekonzerns mit "spekulativer Kauf". Mit Arrowhead erhalte der Anleger eine Art Optionsschein auf die Nanotechnolgie, hieß es.

Beim Blick in das Makler-Oderbuch für die Aktien des chinesischen Nahrungsergänzungsmittelherstellers Starlight Internatinal (WKN: 582 146) war vor allem die Kaufseite gut gefüllt. Der Titel zog von 0,066 Euro auf 0,07 Euro an.

[ Mittwoch, 19.01.2005, 14:42 ]

Quelle: Instock (DE)

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Die Börse Hong Kong gibt als Branche nicht Nahrungsergänzungsmittel an, sondern
Design, manufacture and sale of a wide range of electronic products and securities trading.

Der Emerging Markets Investor nimmt Starlight International
sogar in sein Musterdepot auf.

Die Gesellschaft entwerfe Audio- und Video-Produkte und verkaufe diese Geräte dann an Kunden wie z.B. Wal-Mart, Best Buy oder Carrefour weiter. Die Geschäfte würden sehr vielversprechend laufen.

Noch am 22.12.04 meldet Chong Hing Securities (HK)

(Infocast News) Starlight International Holdings Limited (0485) posted a net profit of $42.163 million for the first half ended September 30, down 48% from a year ago. EPS were $0.0552. An interim dividend of $0.02 per share was declared.

So viel zum Thema Empfehlungen der Börsendienste. Wer sich darauf verläßt, könnte manchmal sein blaues Wunder erleben.

[Paepstin]

Tach zusammen,

ihr solltet euch einmal die "Tochterfirmen" von Arrowhead anschauen. Höchst spannend, vor allem wenn man bedenkt, dass es nur einer kleinen Mitteilung bedarf sollte sich ein Produkt auf dem Markt etablieren. Dann dürfte sich der Kurs entsprechend darstellen.

Viel Glück allen Investierten und einen langen Atem!
Päpstin

[Kostolanys Erbe]

hi paepstin,

finde ich gut, das du arwr auch bei www.nano-invests.de
vorgestellt hast.

so kommen sicherlich noch mehr diskussionen und informationen von vielen leuten zum unternehmen arwr zu tage.


kosto

ps: immer noch auf meiner watchlist, aktuell immer noch im abwärtstrend.

200 tage linie verläuft bei 5 dollar, ist heute an die 50 tage linie gestossen, vorsicht bei bruch nach unten!
was heute auffiel:
umsatzanstieg bei abwärtsbewegung...nicht gut!!!

ARWR Arrowhead Resh Corp (NASDAQ SC) 1/24/2005 3:59 PM


Last:
3.60 Change:
-0.27 Open:
3.96 High:
3.99 Low:
3.56 Volume:
100,268
Percent Change:
-6.98% Yield:
n/a P/E Ratio:
n/a 52 Week Range:
2.02 to 15.00

[Paepstin]

Hi Erbschleicher ,

ich denke, diese Aktie ist allemal so interessant, weil verhältnismäßig jungfräulich!

Gründliche Recherche, vorsichtiges Beobachten und eine langer Atem, könnten hier langfristig ein Sahnetörtchen im Depot bedeuten.

Ich würde mich freuen, wenn sich viele Experten beteiligen und auch den Thread von Nobody_III hier in WO bereichern.

MRASTA, was sagst du denn dazu?

Schönen Abend noch und die besten Wünsche, dass euch der Vollmond nur NANOMÄßIG beeinflusst! Aarrrrrrrrrggggghhhhhhh!

Ich glaube die neuen WO-MODS werden jetzt ihre Vollmond-Feuertaufe antreten müssen! In diesem Sinne fröhliches Schaffen!

Päpstin

[tegtmeier]

Ich finde den Aktionär zwar nicht so toll, aber dieser Artikel hat mich trotzdem interessiert. Habe heute nachgelegt.
http://www.deraktionaer.de/xist4c/web/Top-Themen_id_443__tpl…

[Paepstin]

Trotz des Artikels im Aktionär, hat sich der Kurs wacker gehalten!
Nach dem Gesetz der Serie, sollten nun bald News eintrudeln, die dann die Richtung von 5$ anpeilen.

Schnickschnack,
Päpstin

[Colophonius]

Weitere Pressestimmen zu ARROWHEAD

INSIDE WALL STREET

Why Arrowhead May Outshoot The Nanotechs

Nanotechnology, which involves the design of materials or devices at the molecular level, hasn`t produced many big winners. One stellar performer, however, has been tiny Arrowhead Research (ARWR ), which topped other stocks in the Merrill Lynch (MER ) nanotech index. It zoomed from 1.95 in January, 2004, to 4.32 on Dec. 31. The volatile stock -- not for the faint of heart -- is now at 3.96. The index, made up of 27 nanotech stocks traded in the U.S., has been flat since its Apr. 1 launch. Arrowhead signed a pact in early 2004 with California Institute of Technology to fund Caltech`s nanotech research in exchange for the rights to market future products. Karsten Siebert of Midas Research rates Arrowhead, which has yet to make a dime, a "speculative buy." The company could be the "wild card" among the nanotechs because of its close ties with Caltech, Siebert says. The analyst sees the stock hitting 6 in year. Arrowhead President Bruce Stewart says one product apt to hit the market late this year is an atomic force microscope probe, 1,000 times as sensitive as the existing ones. It lets scientists image and manipulate molecules and atoms in nano dimensions. Advertisement

Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.



By Gene G. Marcial

[michler]

Also ich hab mir mal ein paar gekrallt. Auch wenn der Aktionär seine finger im spiel hat. Irgendwie erinnert mich das Teil an Obducat. Ist auch die selbe zeit des jahres.

Frühjahr = Nano oder was?

Naja jedenfals wenn die nur auf einem gebiet nen durchbruch schaffen könnte das Teil echt abgehn.

[brokeboy]

...diese beteiligungen und vor allem die zahlreichen patente machen arrowhead wirklich interessant. die ersten dämpfer sind überstanden und es kann hochgehen.

[Paepstin]

Genau!
Aber hier sind Geduld und Spucke angesagt!

Immer langsam und stetig mit aufbauen! Kurzfristige Spekulation ist hier nicht gefragt!

Päpstin

[michler]

Hey Leute, Arrowhead war gestern beim Aktionär im "Moneytalk Radio":

10.02.2005 - Arrowhead - Unglaublich günstig!

Aktie im Fokus: Mit einer Anlage in Arrowhead-Papiere schlagen Anleger gleich mehrere Fliegen mit einer Klappe.

http://www.deraktionaer.de/xist4c/web/Deutschlands-grosses-B…

Ich krieg das bei mir nicht zum laufen. Aber wenn wir Glück haben, fängt der bald richtig das Pushen an.

[Colophonius]

Ob hier auch der "Aktionär" dahintersteckt?

ARROWHEAD RESEARCH (NasdaqSC:ARWR) Delayed quote data

After Hours (RT-ECN): 4.41 0.03 (0.68%)

Last Trade: 4.44
Trade Time: Feb 11
Change: 0.30 (7.25%)
Prev Close: 4.14
Open: 4.24
Bid: 4.41 x 200
Ask: 5.75 x 100
1y Target Est: N/A

Day`s Range: 4.10 - 4.63
52wk Range: 1.41 - 9.00
Volume: 298,919
Avg Vol (3m): 124,500
Market Cap: 60.53M
P/E (ttm): N/A
EPS (ttm): -0.24
Div & Yield: N/A (N/A)

[Colophonius]

Hier nochmal die neuen Meldungen zu ARROWHEAD, mal sehen ob das dem Kurs neuen Schwung verschafft:

Press Release Source: Arrowhead Research Corporation

Arrowhead Research Launches New Subsidiary to Focus on Delivery and Therapeutic Use of RNA Interference
Tuesday February 22, 7:00 am ET

PASADENA, Calif.--(BUSINESS WIRE)--Feb. 22, 2005--Arrowhead Research Corporation (NASDAQ:ARWR - News; NASDAQ:ARWRW - News), announced today that it has launched Calando Pharmaceuticals, Inc., a new majority-owned subsidiary. Calando is a nanobiotechnology company focused on developing and commercializing exclusively licensed proprietary technologies for the therapeutic use of RNA interference, or "RNAi." Calando intends to combine novel RNAi delivery technologies, developed at the California Institute of Technology (Caltech), with a scientific leadership team experienced in the areas of non-viral nucleic acid delivery and RNAi.
ADVERTISEMENT


"To our knowledge, this is one of the first nanobiotechnology companies working exclusively on RNA interference. The addition of Calando as an Arrowhead subsidiary further diversifies our portfolio of companies commercializing nanoscale materials and devices for a variety of markets," said R. Bruce Stewart, President of Arrowhead Research Corporation.

RNAi can be used to prevent the expression of specific genes and has the potential to provide new and more effective treatments against various diseases. Calando believes that its exclusively licensed non-viral delivery technologies will enable Calando`s team to overcome the primary hurdle to the therapeutic use of RNAi: an effective delivery mechanism.

In addition to Arrowhead, the founders of Calando include Dr. Mark Davis of Caltech and Dr. John Rossi, a molecular geneticist at the City of Hope`s Beckman Research Institute. Other co-founders include Matt Vincent, a partner at the law firm of Ropes & Gray, who is a recognized expert in the field of intellectual property relating to RNAi, and John Petrovich, who will be CEO of Calando. In exchange for an equity stake, Caltech will license certain RNAi technology to Calando.

Dr. Davis is the Warren and Katharine Schlinger Professor of Chemical Engineering at the California Institute of Technology. He is the Founding Scientist at both Calando Pharmaceuticals and Insert Therapeutics, another majority-owned subsidiary of Arrowhead Research, which is focused on developing proprietary formulations of small molecule drugs and drug delivery systems. Dr. Davis is a leading expert in creating new materials by design and specifically materials for the systemic delivery of nucleic acids.

Dr. Rossi, Chair of the Division of Molecular Biology and Dean of the Graduate School of Biological Sciences of the Beckman Research Institute at the City of Hope, Duarte, California, is widely regarded as a world leader in the development of RNA interference and in clinical research with nucleic acids for the treatment of various diseases. His innovative work over many years at the City of Hope has earned the respect of international scientists and clinicians alike.

The name "Calando" derives from a musical term that means to play slower and softer, and ultimately to die away. "Given the gene-silencing properties of RNAi technology, the name seemed highly appropriate," Dr. Davis said.

About Arrowhead Research Corporation

Arrowhead Research is a nanotechnology company structured to bring together a diverse and innovative mix of technologies, rights to a broad suite of intellectual property, and some of the most respected minds in this dynamic field. There are three strategic components to Arrowhead`s business model:

Forming or acquiring majority-owned subsidiaries engaged in the development and commercialization of nanoscale materials, devices, and systems.
Funding of nanoscience research at universities in exchange for the exclusive right to commercialize resulting intellectual property.
Acquisition, license and sublicense of intellectual property in the field of nanotechnology.
Before the formation of Calando, Arrowhead Research operated three other majority-owned subsidiary companies:

Aonex Technologies, Inc. is developing and commercializing proprietary semiconductor nanomaterial technology.
Insert Therapeutics, Inc. is developing and commercializing proprietary nanometer-sized therapeutics.
Nanotechnica, Inc. is developing capabilities for mass-production of a variety of different, proprietary nanoscale devices and systems.
Arrowhead is also funding three research efforts in nanotechnology at Caltech in the areas of nanomaterials, nanoelectronics, and nanobiomolecular tools.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, without limitation, our developmental stage and limited operating history, our ability to successfully develop products, rapid technological change in our markets, demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.



--------------------------------------------------------------------------------
Contact:
Arrowhead Research Corporation
R. Bruce Stewart, 626-792-5549
[e-mail]


--------------------------------------------------------------------------------
Source: Arrowhead Research Corporation

[Scar]

Noch jemand da?

[glckschweinchen]

hallo allerseits!
hab mir die studie auch durchgelesen und muss sagen das die story fast schon zu posetiv klingt. ich hab mir vor ein paar tagen eine erste position an der nasdaq geholt,weil ich davon ausgehe das es eine schöne langfristposition sein könnte(wegen guten newsflow).
bin zwar sonnst eher kurz bis mittelfrist in aktien,bei arrowhead jedoch könnte ich mir vorstellen das es sich langfristig auszahlen könnte.über meinungen von euch würd ich mich nadürlich freuen.

[Boersenkrieger]

Aha interessant... es gibt ihn tatsächlich in WO... einen thread zu arrowhead

hatte auch mal ein wenig rumgeschnüffelt... irgendwie bin ich aber nicht so richtig bullish geworden, was wohl daran liegt daß sich meine denkschiene etwas verschoben hat:

- arrowhead ist eine aktie von übermorgen, alles ganz am anfang

irgenwie stehe ich derzeit mehr auf fundamentals, auch wenn die technologien nicht mehr so neu sind.. stecke z.b. schon jahre in ner kleine position von Geron. ist irgendwo bei -20 bis -30% mal ne gute phase mal ne schlechte aber es tut sich nichts weil stammzellen-aktien auch noch in einer extrem frühen phase stecken

was für arrowhea spricht ist evtl. daß sie als phantasieaktie noch nicht entdeckt wurden und vielleicht mal ausbrechen könnten um dann zwischen 6 und 12 rumzudümpeln

- ne andere sache ist die... sie sind zwar in vielen bereichen der nanotechnologie vertreten, allerdings was die patente wert sind kann hier wohl keiner sagen, da kennen wir uns zu wenig aus...

was nutzten Millennium z.b. 1000 oder mehr patente ? das ding krebst irgendwo im nirgendwo und auch verluste werden weiterhin fleißig geschrieben und cash verbrannt.

historie:
automobil, eisenbahn, it-branche... was haben wir gelernt ?
wenn es fundamental losgeht... also produkte en masse an den markt kommen und richtig greifbar werden passiert folgendes: 1000e von firmen kommen an den markt, machen sich erst gegenseitig kaputt bis ne hand voll übrigbleibt (in der automobil-branche gab es zwischenzeitlich mal nur 7 (!) firmen) ...allein vom wahrscheinlichkeitsprinzip her ist es da sehr schwer auf nen wert zu setzen der kein verlierer ist.

mein fazit:
arrowhead ist sehr attraktiv und auch recht günstig bewertet (unter phantasieberücksichtigung). trifft aber nur nicht so ganz meinen geschmack.. obwohl ich auch wieder sagen muß daß die 11 titel die ich letztes jahr ins depot gelegt habe angeführt werden von nem phantasiewert: Biophan.. allerdings sind da manche dinge schon absehbar... zumindest wenn die story aufgeht

[Boersenkrieger]

...auch ein satz der mir gut gefällt

Zudem unterstützt man verschiedene Forschungsprogramme auf universitärer Ebene finanziell - im Gegenzug erhält Arrowhead die Vermarktungsrechte.

die strategie insgesamt ist interessant...
arrowhead hab ich auch schon ne ganze weile auf der watchlist... evtl. kauf ich mal ne kleine position. ist mir derzeit nach Biophan die interessanteste nano-aktie...

[Colophonius]

Endlich mal wieder erfreulichere Kursbewegungen im aktuellen Marktumfeld und das bei einem vergleichsweise hohen Volumen:

After Hours (RT-ECN): 4.23 0.01 (0.24%)

Last Trade: 4.22
Trade Time: Apr 4
Change: 0.27 (6.84%)
Prev Close: 3.95
Open: 3.95
Bid: 4.16 x 200
Ask: 4.23 x 800
1y Target Est: N/A

Day`s Range: 3.90 - 4.25
52wk Range: 1.41 - 9.00
Volume: 269,206
Avg Vol (3m): 70,909
Market Cap: 59.57M
P/E (ttm): N/A
EPS (ttm): -0.32
Div & Yield: N/A (N/A)

[Colophonius]

Die neueste Meldung, hoffentlich mal mit einer nachhaltigen Kursbewegung Richtung Norden verbunden:

Press Release Source: Arrowhead Research Corporation

Arrowhead Announces Patent Grant on Spintronic Technology for Use in Next-Generation Semiconductor Devices
Wednesday April 13, 7:00 am ET

PASADENA, Calif.--(BUSINESS WIRE)--April 13, 2005--Arrowhead Research Corporation (NASDAQ:ARWR - News; NASDAQ:ARWRW - News) announced today the U.S. Patent Office issued U.S. patent 6,879,012, Giant Planar Hall Effect in Epitaxial Ferromagnetic Semiconductor Devices. The patent is exclusively licensed to Nanotechnica, Inc., Arrowhead`s majority-owned subsidiary, by the California Institute of Technology.


The patent covers ferromagnetic semiconductor-based methods, devices, and compositions. The technology enables measurements of magnetic spins and enhanced magnetic switching effects, which could play a key role in development of future semiconductor devices based on "spintronics."

Traditional semiconductor devices operate by storing information as charge - an electron`s state represents 0 or 1. In contrast, spintronics taps into the spin of electrons to store or transmit information, which enables next-generation devices for memory, disk storage, magnetic sensors, and quantum computers to be smaller, more powerful, and have longer lives than today`s products.

"This patent covers foundational technology for what we believe will be the next-generation of semiconductor devices," said R. Bruce Stewart, President of Arrowhead. "This patent further strengthens our diversified portfolio of patents in the nanotechnology space. Arrowhead and its subsidiaries now control 36 issued U.S. patents and have licensed over 240 U.S. and international patents and patent applications."

About Arrowhead Research Corporation

Arrowhead Research is a development-stage nanotechnology company structured to bring together a diverse and innovative mix of technologies, rights to a broad suite of intellectual property, and some of the most respected minds in this dynamic field. There are three strategic components to Arrowhead`s business model:

The Commercialization Program: Arrowhead forms or acquires majority-owned subsidiary companies pursuing products based on nanotechnology in high-growth technology markets.
The Research Program: Arrowhead funds nanoscience research at universities in exchange for exclusive rights to license the technology.
The Patent Toolbox: Arrowhead acquires, licenses, and sublicenses intellectual property in nanotechnology.
Arrowhead Research operates four majority-owned subsidiary companies:

Aonex Technologies, Inc., developing and commercializing proprietary semiconductor nanomaterial technology.
Insert Therapeutics, Inc., developing and commercializing a proprietary nanoscale drug delivery system.
Nanotechnica, Inc., developing capabilities for mass-production of a variety of proprietary nanoscale devices, including laboratory on a chip.
Calando Pharmaceuticals, Inc. is developing nanostructures for delivery and therapeutic use of RNA interference.
Arrowhead is funding three research and development efforts in nanotechnology at the California Institute of Technology.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statement on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:
Arrowhead Research Corporation
R. Bruce Stewart, 626-792-5549
[e-mail]

Source: Arrowhead Research Corporation

[nolimitsoldier]

Morgen, mit ihren 240 Patenten ein gut gefülltes Portfolio.Ein aussichtsreiches Unternehmen.Bestimmt schwächelt sie gerade nur.

[Scar]

Kurs bei 4 USD :-)
und gestern hat jemand relativ grosse Stückzahlen für 2,3 € in Frankfurt verkauft.
Krass...

[Scar]

wahnsinn diese Schwankungen. und das ohne News oder gibts doch was neues?

[Scar]

Geht Arrowhead jetzt das Geld aus oder was?

[Boersenkrieger]

naja ist eben ne klitsche.... sind zwar überall mit dabei von den bereichen her... aber masse war noch nie klasse. wer überall mitschwimmen will verliert oft den überblick, vor allem als so kleine firma

[Colophonius]

Wie schätzt ihr das "Rückkaufprogramm" ein ?
(siehe heutige News: Arrowhead Plans to Redeem Stock Purchase Warrants ...)

Gruß C.

[Scar]

Schaue ich mir gleich mal an. Find ich klassen wenn Arrowhead
eigene Aktien zurück kauft. Scheinen zu diesen Kursen ein Schnäppchen zu sein.

[Scar]

Press Release Source: Arrowhead Research Corporation

Arrowhead Plans to Redeem Stock Purchase Warrants
Tuesday April 26, 7:00 am ET

PASADENA, Calif.--(BUSINESS WIRE)--April 26, 2005--Arrowhead Research Corporation (NASDAQ:ARWR - News) today announced its plan to redeem its outstanding redeemable warrants to purchase common stock (NASDAQ: ARWRW - News), subject to certain conditions. The Company`s common stock closed at $2.80 per share on The Nasdaq SmallCap Market on April 25, 2005, triggering the Company`s decision to plan for a warrant call by Friday, May 6, 2005. Under their terms, the warrants may be called so long as certain trading conditions are met, namely, the Company`s common stock must trade at $3.00 or above for 20 consecutive trading days ending not less than 15 days preceding the date of redemption ("Market Condition"). The price of common stock remained at or above $3.00 throughout 2005 until yesterday, and, accordingly, the Company must redeem the warrants in the next 15 days or satisfy the Market Condition for future redemption.

[Boersenkrieger]

Rückkaufprogramme sind immer großes kino... meist steigt der kurs dann auch

[Scar]

Ich frag mich nur warum der Kurs dann jetzt so ins Bodenlose stürzt.
Die Meldung verstehe ich nicht ganz. Ist da wirklich ein Aktienrückkaufprogramm gemeint? Was heisst "Arrowhead Plans to Redeem Stock Purchase Warrants"
Warrants sind doch Optionsscheine. Wollen die irgendwelche Bezugsrechte aus Optionsscheine wahrnehmen?

[superman]

Arrowhead hatte früher schon diese Optionsscheine ausgegeben mit einem Bezugskurs von 1,50$. Das ist nichts neues und die Ausübung war nur eine Frage der Zeit und die Verwässerungs mußte eigentlich ständig berücksichtigt werden. Jetzt hat Arrowhead von dem Recht Gebrauch gemacht die Optionsscheine quasi zu kündigen und wer sie ausüben will muß es jetzt tun und quasi 1,50$ in die Firma einschiessen, sodaß die deutlich über 20 Mio$ an Cash erhalten. Was passiert also im Moment? Die Leute, die vermutlich Aktien und die Optionsscheine haben verkaufen schonmal ihre Aktien über 1,50$, da sie ja jetzt nochmal welche beziehen (wohl zwangsläufig wenn sie ein Geschäft machen). Und es gibt offenbar noch ein paar Anleger, denen das mit den Optionsscheinen neu war und eine Verwässerung befürchten, was aber wie gesagt nichts neues ist. Hatte Arrowhead auf der Watchliste und habe sie gestern gekauft. a) steht jetzt eine langfristige Finanzierung b) scheint das Portfolio einmalig auf der Welt zu sein (gebe zu kenne mich nicht gut aus - glaube aber mal den Berichten zu Arrowhead) c) ist der Kursverfall ein reines Gewinnmitnahmespiel für die Optionsscheininhaber, was den sonstigen Aktionären denke eine einmalige Einstiegsgelegenheit in diesen Wert zu diesen Konditionen bietet. Für mich ein Superstrong-buy - man braucht aber zur Entfaltung der ganzen Story lange Zeit. Aber die Firma steht denke ich besser denn jeh da und der Nachrichtenfluß aus den Beteilugungen klingt ja zuletzt auch sehr interessant. Werde hier kein Dauerposter - das mal nur kurz zur aktuellen Lage.

[Scar]

Danke für den Beitrag. Das wird die Erklärung sein. 5:13 Uhr nicht schlecht ;-)

Zu 1,50 USD haben wir ja durchaus noch ein wenig Potential nach unten :-(

Habe gestern zu 1,93 € nachgekauft, weil sich an den fundamentals nichts geändert hat. Wenns weiter runter geht,
lege ich nochmals nach. Langfristig, aber auch auf Dauer von einem halben Jahr eine tolle Gelegenheit.

[superman]

Scheint, daß die Anleger doch langsam realisieren, daß wir die ausstehenden Optionsscheine schon vorher hatten und deren Einlösung die Finanzierung für die Firma sichert und Klarheit für die Zukunft schafft. Die Einlösung wäre ja so oder so gekommen. Die Anzahl der Optionsscheine ist sehr hoch und daher werden wir noch sehr wilde Schwankungen erleben, zwischen denen die kaufen und denen die diese Gewinne zur Zeit mitnehmen wollen. Da die Firma über enormes Potential verfügt denke ich, daß in den nächsten Wochen zwangsweise der Kurs steigen muß, wenn diese künstliche Deckelung nachlässt. Der heutige Tag zeigt für den sicherlich vorhandenen Angebotsdruck eine große innere Stärke. Aber sehr viele haben wohl gemerkt, daß es hier im Moment eine Zukunftsaktie mit gigantischem Potential zu Ausverkausfpreisen gibt.

[Scar]

Ich denke, dass die die verkaufen wollten, jetzt geschmissen haben. Die anderen die ihre Aktien über die Optionsscheine für 1,50 bekommen haben, verkaufen jedoch nicht zu diesen
Dumpingpreisen nur um die paar Cent Gewinn zu realisieren, weil sie - wenn sie warten - mehr bekommen.
Der grosse Abgabedruck dürfte vorbei sein.

[Colophonius]

Eine weitere, insgesamt positive Einschätzung zu ARROWHEAD wie ich finde, hier aus der Ecke von "Motley Fool", tja, nur der Kurs ...

Nano Moves to the Mainstream
By Carl Wherrett (TMF Breaker Carl) and John Yelovich (TMF Breaker John)
April 28, 2005

It`s been fascinating to watch nanotechnology slowly advance from theory to reality. For investors, however, only one journey really matters: The step from the research laboratory to commercial product.

As investors, we keep the majority of our powder dry, firmly believing that many of the best Rule Breaking nano investments are yet to come. We do note, however, that some opportunities already exist. One of these opportunities is in the incubators of budding nano companies, called technology transfer companies. A technology transfer company is an organization designed to take the research efforts of universities (or sometimes private corporations that do not wish to develop new ideas internally) and bridge the gap between concept and commerce.

There are three publicly traded incubators in the nano universe (that we know of). They possess a high-risk profile but of course stand to reap all the rewards of a successful investment. The three incubators are Arrowhead Research (Nasdaq: ARWR), Competitive Technologies (AMEX: CTT), and a very new entrant to the nanotech universe, Advance Nanotech (OTCBB: AVNA).

Arrowhead Research
Arrowhead Research used to be known as Interactive Inc., but through a reverse acquisition by Arrowhead founder Bruce Stewart, it was renamed in January 2004. Its primary focus is to develop and commercialize the nano research and proprietary products being developed at the California University of Technology. Arrowhead has already established three majority-owned subsidiaries, each focused on a particular sector of nano development.

Aonex Technologies was formed to commercialize a proprietary process for fabricating semiconductor nanomaterials to help device manufacturers reduce costs and improve performance. In the near term, Aonex is focused on applying its technology to next-generation solar cells.

Another subsidiary, Insert Therapeutics, received $5 million of funding from Arrowhead in 2004 in return for 62% of the company. Insert is developing advanced drug delivery technologies with a proprietary polymer delivery system trademarked as Cyclosert. This last round of funding was primarily raised to finance preclinical and phase 1 trials for their lead product, Cyclosert-camptothecin. Camptothecin is an anti-cancer agent that has been around for more than 40 years but has yet to be commercialized in its pure form because of toxicity issues related in part to its poor solubility. The company is hoping to demonstrate that its technology overcomes those problems and that the product will be superior to camptothecin derivatives such as Camptosar, which is made by Pfizer (NYSE: PFE).

The final subsidiary, Nanotechnica Inc., was funded with $4 million by Arrowhead in return for 74% of the company and is developing nanoscale devices and systems.

All of these subsidiaries are a long way from actual revenues. Arrowhead`s role is to ensure that they have sufficient financial and material backing to allow them the time to develop a commercial product and attract partners and customers. According to its latest 10-Q, Arrowhead`s only revenue source thus far is $129,000 in grant revenue brought in by Insert. With less than $7 million in cash and burning nearly $2 million a quarter, Arrowhead was in desperate need of a cash infusion. This week it announced the exercise of warrants raising $21 million, which puts it in a much healthier position to continue the efforts of its subsidiaries, as well as to continue sponsoring further nano research by Caltech.

Competitive Technologies
Competitive Technologies was established in 1971 and has been acting as the bridge for more than 500 separate licensing agreements between universities and industries. It has licensed developments across a variety of sectors, including electronics, biotechnology, and, lately, nanotechnology. It is working with the University of South Carolina in developing a nano-derived bone biomaterial that is reportedly superior to existing bone cement products.

Competitive`s share price rose more than 345% in 2004, but a peek under the covers indicates that this growth isn`t sustainable without further developments. The rise was primarily a result of two separate one-time payments that boosted revenue growth. The first payment was a portion of a $50 million settlement from Wyeth, which had infringed upon a University of Colorado patent. Although Competitive Technologies was not a direct litigant, it received about $5 million of the payment because of its contract with the university. The second windfall was a $5 million up-front license fee paid by Abbott Laboratories for a hymocysteine assay patent. That patent expires in 2007, leaving Competitive little time to accrue much more than $1 million to $2 million in further royalties. If we back out those fortuitous one-off payments, the company is not much different from what it was a year ago, when it was under review for delisting by AMEX. The share price was $4 then; it is now more than $10.

Advance Nanotech
Within the space of nine months, the newest of the technology transfer companies, Advance Nanotech, has gone from nonexistence to sitting at some impressive dining tables.

In July 2004, Advance Nanotech made a $2 million investment in a fellow British company, Owlstone Ltd., in exchange for 60% of the company. Owlstone was spun out of Cambridge University and is developing nanosensors for detection of chemicals and explosives, with markets in homeland security and personal safety. In October 2004, Advance Nanotech backed itself into the existing U.S. public listing of Artwork & Beyond. Advance paid off Artwork & Beyond`s directors and established a new name, new ticker, and new directors.

Since becoming publicly listed in the U.S. market, Advance Nanotech has established 18 nano subsidiaries and is in the process of breathing life into each one. To do so, it raised $20 million in a share offering in February 2005 that included several VC companies and a polyglot of ex-chairmen and CEOs, including Michael Jordan, chairman and CEO of EDS and former CEO of Westinghouse and CBS; Jonathan Segal, founder of WorldPay; Larry D. Bouts, former chairman and CEO of Six Flags Theme Parks and former CEO of Toys "R" Us International; Greg Osborn, co-founder and partner of IndiGo Securities and former senior vice president at Smith Barney; and Timothy Lane, former chairman and CEO of Holiday Inn Worldwide and former president of Frito-Lay International.

Advance Nanotech is among the lead partners in the financing of Cambridge University`s new Center for Advanced Photonics and Electronics, a facility designed to bring together the disparate nano research groups in Cambridge under one roof. Cambridge University is the preeminent university in the U.K. (arguably in all of Europe), and it has educated more than 60 Nobel Prize winners. This new center of excellence is positioned to become one of the leading nano research institutions in the world, and Advance Nanotech is a lead partner in the venture. Other partners include Marconi (Nasdaq: MRCIY), ALPS Electrical Company, and Dow Corning, a joint venture between Corning (NYSE: GLW) and Dow Chemical Co. (NYSE: DOW).

Advance Nanotech has also opened offices in the United States and one in the Far East, with a $3.5 million budget to invest in emerging nanotechnology research. Its original investment in Owlstone could bear fruit as soon as the end of this year, since Owlstone promises a commercial launch of its button-sized sensors by then. The nano component is in fabrication and promises to be 1,000 times cheaper than existing chemical sensors.

Ordinarily, a bulletin board stock that comes out of nowhere touting the latest hot technology and promising the world would raise a huge red flag. In this case, however, we`re taking a closer look.

When looking for potential Rule Breakers, we scout companies that take our breath away. Advance Nanotech has certainly done that with the pace of their development. Although it is burning through a lot of cash, will it fly too close to the sun and fall back down to earth? Only time will tell. We advise you to take your time and thoroughly research this company.

As you can see, these are all highly speculative stocks. Investors with a risk-averse disposition should look elsewhere. Those with a penchant for risk (and reward) might want to take the view that Caltech and Cambridge University are likely to produce pioneering developments in nanotechnology -- developments that can make it to a commercial market. If so, then the work being done now by Arrowhead Research and Advance Nanotech could reap investment benefits for the long term. Competitive Technologies is less focused on nanotechnology and currently looks overpriced, but it does have more history on its side.

[Colophonius]

Das Eichhörnchen sammelt fleissig weiter ... ob`s der Markt irgendwann mal realisiert ?
Gruß C.

Press Release Source: Arrowhead Research Corporation

Arrowhead Research Corporation Acquires Early Nanosensor Patent Portfolio
Thursday May 19, 7:00 am ET

PASADENA, Calif.--(BUSINESS WIRE)--May 19, 2005--Arrowhead Research Corporation (NASDAQ:ARWR - News; NASDAQ:ARWRW - News) announced today that it has acquired a suite of patent and patent applications covering nanosensor technology developed by Dr. Hermann Gaub, a Professor of Biophysics at the Center for Nanoscience at Ludwig-Maximilians University in Munich. Arrowhead and its subsidiaries now own or have licenses to over 250 U.S. and international patents and patent applications.
"Nanosensors are expected to radically change the way we diagnose disease. Now, we go to the doctor`s office to have large samples of blood taken and then wait for days to get the results from a remote laboratory," said R. Bruce Stewart, President of Arrowhead. "With a nanosensor-enabled device, tests could be performed with a single drop of blood - and the results obtained within minutes."

The portfolio covers techniques for measuring biomolecular interactions by single-molecule force spectroscopy. As reported in "Science" in 2003, the devices are sensitive enough to detect single-base pair mismatches of DNA and have demonstrated significant improvement over state-of-the-art instrumentation. The patent applications also cover construction of parallel assays for placing millions of sensors on a chip. These patent and patent applications were acquired for a di minimus cash payment and are complementary to other patents to which Arrowhead already has rights

[Colophonius]

So langsam scheint die Talsohle vorerst mal durchschritten - oder was meint ihr ? Auch das Volumen war vergleichsweise hoch:

ARROWHEAD RESEARCH (NasdaqSC:ARWR)Delayed quote data

Last Trade: 2.74
Trade Time: May 31
Change: 0.14 (5.38%)
Prev Close: 2.60
Open: 2.63
Bid: 2.40 x 2000
Ask: 2.75 x 5000
1y Target Est: N/A

Day`s Range: 2.63 - 2.78
52wk Range: 1.41 - 8.00
Volume: 166,733
Avg Vol (3m): 91,142
Market Cap: 38.68M
P/E (ttm): N/A
EPS (ttm): -0.29
Div Yield (ttm): N/A (N/A)

Gruß C.

[Colophonius]

Press Release Source: Arrowhead Research Corporation

Exercise Deadline for Arrowhead`s Warrant Redemption is Tuesday, June 14, 2005 -- Redemption Scheduled to Close Wednesday, June 15, 2005
Thursday June 2, 7:00 am ET

PASADENA, Calif.--(BUSINESS WIRE)--June 2, 2005--Arrowhead Research Corporation (NASDAQ:ARWR - News) will redeem its outstanding warrants to purchase common stock (NASDAQ:ARWRW - News) on Wednesday, June 15, 2005, as previously announced on May 4, 2005. The last day to exercise warrants (the exercise deadline) is Tuesday, June 14, 2005. Arrowhead intends to de-list the warrants from The Nasdaq SmallCap Market on Wednesday, June 8, 2005, to allow for an orderly redemption.
The warrants are exercisable for $1.50 per share and are redeemable at the redemption price of $0.001 per warrant. Any warrant not exercised by Tuesday, June 14, 2005, will expire and will be redeemed by the Company for $0.001 per share.

To date, 3.3 million of the 13.8 million warrants originally issued have been exercised. There are remaining approximately 10.6 million outstanding warrants. If all of these outstanding warrants are exercised, the Company will have received, in total, approximately $21 million in exercise proceeds. The Company anticipates using the proceeds to fund the Company`s subsidiaries, to fund the Company`s research projects and for general working capital.

[Colophonius]

Trotz der Nachrichtenlage bleibt der Kurs im Keller :

Press Release Source: Arrowhead Research Corporation

Arrowhead Announces License of New Nanotech Stem Cell Device from Stanford University
Monday June 6, 7:00 am ET

PASADENA, Calif.--(BUSINESS WIRE)--June 6, 2005--Arrowhead Research Corporation (NASDAQ:ARWR - News) announced today that it has exclusively licensed intellectual property from Stanford University for a nanotech device that controls the behavior of adult stem cells. Arrowhead will fund additional research involving the device at Stanford in exchange for the right to exclusively license and commercialize the technology.
The technology has been developed in the lab of Dr. Nick Melosh in the Materials Science Department at Stanford. The Melosh group is using arrays of nano-reservoirs on a chip to stimulate desired adult stem cell behavior. Melosh`s team will conduct further research by collaborating with scientists and doctors at the Stanford Stem Cell Institute and the Lucile Packard Children`s Hospital. Arrowhead has committed $600,000 to the project, with $110,000 funded upon signing and the remainder payable quarterly over the following two years.

Both embryonic and adult stem cells have the ability to become the cells of different tissues and represent a treatment for diseases such as neurological disorder, heart failure, and diabetes. Adult stem cells, which are less controversial from a political standpoint than embryonic stem cells, are less likely to generate immune reactions in patients and, therefore, could be better suited for tissue engineering than embryonic stem cells. Notwithstanding the potential of adult stem cells, however, there is no commercially available tool to enable scientists and doctors to precisely control their functions. "The solution we are pursuing is to build a device that can interact with the stem cell at the micro- and nanoscale," said Dr. Melosh. "For example, exposure to minute amounts of chemical at the appropriate time and place could be the key for guiding stem cells isolated from fat tissue to turn into cartilage or bone constructs."

"We are pleased to expand our outsourced R&D and commercialization program to Stanford," said R. Bruce Stewart, President of Arrowhead. "We believe nanotechnology is the key to unleashing the potential of stem cells. Ultimately, surgeons could use this product to grow heart tissue in the Emergency Room to replace damaged tissue resulting from a heart attack."

[Colophonius]

Liegt hier womöglich die Ursache ?

Press Release Source: Arrowhead Research Corporation

Arrowhead Revises Commercialization Strategy with Respect to Patents Licensed to Majority-Owned Subsidiary, Nanotechnica, Inc.
Monday June 6, 5:47 pm ET

PASADENA, Calif.--(BUSINESS WIRE)--June 6, 2005--Arrowhead Research Corporation (NASDAQ:ARWR - News) announced today that a majority of the shareholders of Nanotechnica, Inc. have voted to dissolve Nanotechnica, Inc. In light of the dissolution, Arrowhead will not make contemplated additional capital contributions of $16 million to Nanotechnica.
A portion of Nanotechnica`s intellectual property portfolio covering microfluidic-based devices has been transferred to Arrowhead. "Arrowhead intends to pursue a more cost-effective approach to integrating microfluidics with nanoscale devices and to commercializing this promising technology," said R. Bruce Stewart, President of Arrowhead.

[Colophonius]

Ist damit in Kürze der Druck raus ?

Press Release Source: Arrowhead Research Corporation

Arrowhead`s Warrants to Delist at Close of Business on June 8, 2005 in Anticipation of June 14, 2005 Exercise Deadline
Tuesday June 7, 7:00 am ET

PASADENA, Calif.--(BUSINESS WIRE)--June 7, 2005--Arrowhead Research Corporation (the "Company") will delist its warrants to purchase common stock (the "Warrants") (NASDAQ:ARWRW - News) from The Nasdaq Stock Market after the close of business on Wednesday, June 8, 2005. The Company is delisting the Warrants as part of its previously announced Warrant Redemption plan. Warrant holders will be able to exercise their Warrants after delisting, until 4:00 PM PT on Tuesday, June 14, 2005 (the "Exercise Deadline"). Unless the Exercise Deadline is extended, Warrants not properly exercised by the Exercise Deadline will be redeemed by the Company for $0.001 per share on Wednesday, June 15, 2005.
Currently the Company has 18.3 million shares of common stock and 9.9 million common stock purchase warrants outstanding. If all these outstanding warrants are exercised, the Company will have received, in total, approximately $21 million in exercise proceeds. The Company anticipates using the proceeds to fund the Company`s subsidiaries, the Company`s research projects and for general working capital.

[GAHN]

der Druck ist raus und Arrowhead kann und ist wieder
gestiegen
hab dank Deiner info bei 2,05 gekauft

würde mich freuen wenn
dieser Thread aktiver wär.

[Scar]

Denke auch, daß es aufgrund Auslaufen der Warrants bald zu wesentlich höheren Kursten kommt. Bin nur leider auch zu wesentlichen höheren Kursen eingestiegen.

[GAHN]

Frage an colophonius:

hab Arrowhead im Depot als kleine Beimischung -

da du Dich wie ich glaube schon sehr viel länger

mit Arrowhead beschäftigst als ich was traust Du

der Aktie im Zeitfenster von 3-5 Jahren zu ?


Gahn

[Colophonius]

@gahn
Kursziele kann ich eigentlich keine ruhigen Gewissen formulieren, ist halt ein höchst spekulativer Wert. Ich empfehle vielmehr, ein bißchen am Anfang dieses Threads zu stöbern. Hier gibt neben vielen interessanten und, wie ich finde, fundierten Beiträgen (siehe u.a. Päpstin, Nobody III, Suncomesout)auch Aussagen zu Kurszielen. Ich für meinen Teil sitze momentan übrigens noch auf ordentlichen Minusprozenten, da zu früh eingestiegen. Beim nächsten Nanohype hat meiner Meinung nach jedoch Arrowhead gute Chancen weit vorne zu landen.

Gruß C.

[Colophonius]

Mal schauen, ob der Kurs jetzt anspringt:

Press Release Source: Arrowhead Research Corporation

Arrowhead Completes Warrant Redemption
Thursday June 16, 7:00 am ET
Receives over $20 Million in Net Proceeds

PASADENA, Calif.--(BUSINESS WIRE)--June 16, 2005--Arrowhead Research Corporation (NASDAQ:ARWR - News) today announced that almost all of its outstanding redeemable warrants to purchase common stock were exercised prior to the exercise deadline of 4:00 PM PT on Tuesday, June 14, 2005. The net proceeds of over $20 million in cash will be used to fund the Company`s subsidiaries, the Company`s research projects and general working capital purposes.
"We continually see exciting opportunities in nanotechnology. Having a strong cash position will allow us to act quickly when the right opportunities are identified," said R. Bruce Stewart, President of Arrowhead. "The proceeds from the warrant call will allow Arrowhead to continue to fund existing companies, to expand our research programs, and to continue implementing our overall business plan."

[Scar]

Arrowhead ist m.E. ein ideales Langfristinvestment. Bis man mit Nanotechnoligie gut Geld verdienen kann wir noch einige Zeit vergehen. Arrowhead ist jedoch bestens aufgestellt und wird ganz vorne mit dabei sein. Früher oder später merken das einige. Gehe davon aus, daß wir bald wieder über 3 € notieren

[Colophonius]

Mal wieder ein ordentliches Plus, aber leider nur ein eher mäßiges Volumen:

ARROWHEAD RESEARCH (NasdaqSC:ARWR) Delayed quote data

Last Trade: 2.6299
Trade Time: Jun 16
Change: 0.1699 (6.91%)
Prev Close: 2.46
Open: 2.48
Bid: 2.55 x 1000
Ask: 2.63 x 1000
1y Target Est: N/A

Day`s Range: 2.48 - 2.63
52wk Range: 1.41 - 8.00
Volume: 97,062
Avg Vol (3m): 110,388
Market Cap: 37.12M
P/E (ttm): N/A
EPS (ttm): -0.294
Div Yield (ttm): N/A (N/A)

[Colophonius]

Auf dem Schlusskurs von Freitag lässt sich aufbauen

Last Trade: 2.82
Trade Time: Jun 17
Change: 0.19 (7.23%)
Prev Close: 2.63
Open: 2.63
Bid: 2.60 x 1100
Ask: 2.99 x 2000
1y Target Est: N/A

Day`s Range: 2.63 - 2.85
52wk Range: 1.41 - 8.00
Volume: 133,490
Avg Vol (3m): 112,218
Market Cap: 39.80M
P/E (ttm): N/A
EPS (ttm): -0.29
Div Yield (ttm): N/A (N/A)

Auf eine weiterhin erfreuliche Kursentwicklung.
Gruß C.

[Scar]

Nach dem Auslaufen der Warrants werden wir wohl bald wieder bei unserem März/April Kurs von 4 USD sein. Fundamental hat sich ja überhaupt nichts verschlechtert.

[wullux]

Press Release Source: Arrowhead Research Corporation


Arrowhead Announces Licensing by Subsidiary of RNAi Delivery Technology to Benitec
Tuesday June 21, 7:00 am ET


PASADENA, Calif.--(BUSINESS WIRE)--June 21, 2005--Arrowhead Research Corporation (NASDAQ:ARWR - News) announced today that its majority-owned subsidiary, Calando Pharmaceuticals Inc., has granted an exclusive worldwide license to Benitec Ltd. (ASX:BLT - News) for the combination of Calando`s polymeric nucleic acid delivery technology with Benitec`s RNA interference (RNAi)-based therapeutic for hepatitis C virus (HCV). The new technology created by this partnership represents an entirely new therapeutic approach to treating HCV, presently largely incurable and resistant to treatment. HCV is the most common blood-borne infection and the biggest cause of liver transplants in the United States. Calando will receive an upfront payment, milestone payments and royalties on revenue from this HCV therapeutic.
We are pleased to be working with Benitec," said R. Bruce Stewart, Arrowhead`s President. "It has been estimated that the market for HCV therapeutics could approach $4 billion, and this collaboration represents the first step in executing our strategy in the RNAi therapeutics marketplace."

About Arrowhead Research Corporation

Arrowhead Research Corporation is a diversified nanotechnology company structured to commercialize products expected to have revolutionary impacts on a variety of industries, including materials, electronics, life sciences, and energy.

There are three strategic components to Arrowhead`s business model:

Outsourced R&D Program: Arrowhead identifies patented or patent-pending technologies at universities or government labs and funds additional development of those technologies in exchange for exclusive rights to commercialize the resulting prototypes. Leveraging the resources and infrastructure of these institutions provides Arrowhead with a highly cost-effective development pipeline. Currently, Arrowhead is supporting efforts in stem cell technology, nanomaterials, nanoelectronics, and nanobiotools at the California Institute of Technology and Stanford University.
Commercialization Program: After prototypes have been sufficiently developed in the laboratories, Arrowhead forms or acquires majority-owned subsidiaries to commercialize the technology and provides the subsidiaries with strategic, managerial, and operational support. At present, Arrowhead owns majority interest in subsidiaries commercializing diverse technologies, including anti-cancer drugs, RNAi therapeutics, and compound semiconductor materials.
The Patent Toolbox: Arrowhead has acquired or exclusively licensed patents and patent applications covering a broad range of nanotechnology. The Company is actively seeking to add to this intellectual property portfolio.
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statement on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.



--------------------------------------------------------------------------------
Contact:
Arrowhead Research Corporation
R. Bruce Stewart, 626-792-5549
[e-mail]





Press Release Source: Benitec Ltd.; Calando Pharmceuticals Inc.


Benitec Granted Exclusive Worldwide License to Calando`s RNAi Delivery Technology for Benitec`s Hepatitis C Therapeutic
Tuesday June 21, 7:20 am ET


MOUNTAIN VIEW, Calif. and DUARTE, Calif., June 21 /PRNewswire-FirstCall/ -- Benitec Ltd. (ASX: BLT - News) and Calando Pharmaceuticals Inc., a majority-owned subsidiary of Arrowhead Research Corporation (Nasdaq: ARWR - News), announced today that Calando has granted an exclusive worldwide license to Benitec for use of its polymeric nucleic acid delivery technology. Benitec will use Calando`s technology in combination with its RNA interference (RNAi)-based therapeutic for hepatitis C virus (HCV). The new technology created by this partnership represents an entirely new therapeutic approach to treating HCV, presently largely incurable. HCV has a market potential in excess of $US 4 billion per year.
ADVERTISEMENT


"This collaboration is a major advance in fulfilling the promise of RNAi therapeutics. Benitec, a pioneer and leading IP holder in RNAi, continues to significantly contribute to this field," stated Sara Cunningham, CEO of Benitec, adding, "Drs. Mark Davis and John Rossi, co-founders of Calando, and Dr. Mark Kay, one of the leaders of our Scientific Advisory Board and a strategic advisor to Benitec, have been remarkably productive and creative collaborators in the area of non-viral delivery of novel therapeutics. The Benitec-Calando collaboration is borne of their collective expertise and it is to the benefit of patients and shareholders alike that we are able to move this potential blockbuster drug toward the clinic."

"This outstanding combination of scientific teams promises to advance both companies` technologies, along with the viability of RNAi therapeutics generally, to a new level," stated Calando CEO John Petrovich. "This is consistent with our strategy to bring several RNAi therapeutics to the clinic in the near term."

Calando`s non-viral technology breaks new ground in the systemic delivery of RNAi molecules. As RNAi molecules are large from a molecular standpoint and not readily taken up by cells, treating diseases that cannot be accessed topically or by direct injection into a particular organ or at the disease site has been problematic. Calando scientists have shown recently that intravenous injection of nanoparticles comprised of Calando`s proprietary cyclodextrin-containing polymers and an RNAi drug had a significant therapeutic effect in a small animal model of Ewing`s Sarcoma. Cyclodextrins, used in various forms in several US Federal Drug Administration (FDA) approved drugs, do not trigger an immune response and have shown no toxicity at dosages far in excess of those intended for use with RNAi. Benitec-Calando nanoparticles will be developed to specifically penetrate liver cells infected by HCV and will enable repeat dosing similar to approved small molecule drugs for HCV.

Calando will receive an upfront payment, milestones and royalties on revenue from this HCV therapeutic, however the financial details of the agreement were not disclosed.

About RNAi

RNAi has emerged as a powerful new technology for the treatment of virtually any disease with a genetic basis, whether that be the inappropriate over-expression of genes such as with cancer and autoimmune diseases, or when the disease-causing agent itself is DNA or RNA, for instance HIV and HCV. What RNAi offers is an entirely new approach to treating these unmet medical needs.

About Benitec

Benitec is an international biotechnology company focused on developing therapeutics to treat serious diseases using its proprietary RNAi technology. Benitec is listed on the Australian Stock Exchange and has its operations centered in the heart of Silicon Valley in Mountain View, California, USA. Its lead therapeutic programs are for Hepatitis C Virus (HCV) and the Human Immunodeficiency Virus (HIV). Benitec`s RNA-based HIV therapeutic, co- developed with the Center for Biomedicine & Genetics at the City of Hope in Los Angeles, California, will enter Phase I clinical trials in 2006. Benitec`s RNAi therapeutic for HCV will enter clinical trials in late 2006. For additional information, please visit http://www.benitec.com .

About Calando

Calando Pharmaceuticals Inc. is a privately held biopharmaceutical company funded by Arrowhead Research Corporation and located in a City of Hope research building immediately adjacent to the main campus. Calando is using its proprietary technologies to design and create new, targeted siRNA therapeutics. Calando combines proprietary technologies in targeted polymeric delivery systems and siRNA design to create effective therapeutics. The company is pursuing this goal through its internal research and development and also through collaborations and partnerships with pharmaceutical and biotechnology companies. For more information, visit http://www.calandopharma.com .

Forward-looking Statements

This press release contains forward-looking statements that reflect the Companies` current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Companies` research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.


CONTACTS:

BENITEC LTD.
United States:
Laurie Reisinger
650 564 9850 ext.1101
[e-mail]

THE RUTH GROUP
Zack Kubow
646 536 7020
[e-mail]

CALANDO
John Petrovich
President & CEO
Calando Pharmceuticals Inc.
626 305 9322
[e-mail]




--------------------------------------------------------------------------------
Source: Benitec Ltd.; Calando Pharmceuticals Inc.

[Colophonius]

So kann`s weitergehen, endlich reagiert der Kurs mal entsprechend auf gute Nachrichten

ARROWHEAD RESEARCH (RT-ECN)
Symbol: ARWR
Last Trade: 3.08 10:00AM ET
After Hours Change: N/A
Today`s Change: 0.20 (6.80%)
Bid: 3.03
Ask: 3.09

[Colophonius]

Aufwachen, es kommen wohl bewegte Zeiten auf uns zu ...
ARROWHEAD RESEARCH (NasdaqSC:ARWR) Delayed quote data

Last Trade: 3.20
Trade Time: Jun 21
Change: 0.32 (10.96%)
Prev Close: 2.88
Open: 3.00
Bid: 2.95 x 1000
Ask: 2,000.00 x 100
1y Target Est: N/A

Day`s Range: 2.95 - 3.20
52wk Range: 1.41 - 8.00
Volume: 415,307
Avg Vol (3m): 119,132
Market Cap: 45.17M
P/E (ttm): N/A
EPS (ttm): -0.29
Div Yield (ttm): N/A (N/A)

[Scar]

und der nächste Stop ist - wenn überhaupt - erst bei 4 USD

[Scar]

#72
Bezüglich Meldung:
Kennt sich jemand in der Materie aus und kann die Bedeutung der Kooperation für Arrowhead bewerten?

Die Nachricht besagt doch, daß die Arrowheadtochter Calando mit Benitec hinsichtlich eines Hepatitis C Medikaments zusammenarbeitet bzw. die weltweite Lizenz für ein Verfahren erteilt hat, mit dem das Medikament hergestellt wird oä ?
Hab ich das richtig verstanden.

Ich finde es nur schwer einzuschätzen in welcher Größenordnung dadurch Gewinn zu erwarten ist.

[0815bulli]

Wie ist denn Arrowhead im Vergleich zu Nano-Proprietary zu sehen? Die haben doch auch ein interessantes Patent-Portfolio aufgebaut - und werden hier in keiner aktiven Diskussion berücksichtigt. Obwohl heute bspw. wieder interessante Kursbewegungen vorhanden sind.

[Scar]

Schade daß hier nix mehr los ist...

[Colophonius]

Hurra, zumindest mal wieder eine Nachricht - nur ob`s was bringt ?
Press Release Source: Arrowhead Research Corporation


Arrowhead Announces SBIR Award to Subsidiary for Improved Solar Cells
Thursday August 11, 7:00 am ET


PASADENA, Calif.--(BUSINESS WIRE)--Aug. 11, 2005--Arrowhead Research Corporation (NASDAQ:ARWR - News) announced today that a majority-owned subsidiary, Aonex Technologies, Inc, has been awarded a Phase I SBIR grant to use its proprietary process to advance a new class of more powerful and more efficient solar cells. "New nano-enabled energy technologies are gaining increased attention from both industry and government," said R. Bruce Stewart, Arrowhead`s President. "We are pleased that Aonex has been awarded an SBIR grant to support this particular application of its technology. A key component of Arrowhead`s strategy is to leverage public sector funding to further our technologies while keeping our costs down."
The Aonex proprietary process uses lighter weight substrates to enable solar cells that are more efficient, more powerful and less expensive to manufacture. The Phase I grant is approximately $100,000. Successful completion of Phase I efforts could result in a Phase II award of up to $750,000.

Aonex is commercializing a proprietary process for fabricating semiconductor nanomaterials to help device manufacturers in several markets reduce costs and improve performance. Aonex is currently applying its technology to next-generation solar cells and other optoelectronic devices. Longer term, the company seeks to enable devices with optical, logical, and amplification features on a single substrate.

Contact:
Arrowhead Research Corporation
R. Bruce Stewart, 626-792-5549
[e-mail]

Source: Arrowhead Research Corporation

[Paepstin]

Sorry!
Aber diese blöde Mistaktie hätte ich mir ersparen sollen!

Päpstin

[Colophonius]

Falls es jemanden interessieren sollte:

Press Release Source: Arrowhead Research Corporation

Esteemed Scientist Joins Arrowhead Scientific Advisory Board
Tuesday August 16, 7:00 am ET

PASADENA, Calif.--(BUSINESS WIRE)--Aug. 16, 2005--Arrowhead Research Corporation (NASDAQ:ARWR - News) announced today that Dr. Thomas A. Tombrello has agreed to join its Scientific Advisory Board. Dr. Tombrello is the Chairman of the Division of Physics, Mathematics, and Astronomy at the California Institute of Technology and is the William R. Kenan, Jr. Professor of Physics. He has served as Caltech`s Technology Assessment Officer since 1996. In this role, Dr. Tombrello is responsible for identifying and evaluating new and promising technologies for the Institute. From 1987 to 1989, Dr. Tombrello was Vice President and Director of Research at Schlumberger-Doll Research.

"We are delighted to have Tom as the newest member of our Scientific Advisory Board," said R. Bruce Stewart, Arrowhead`s President. "His technical expertise and business savvy will be extremely valuable in guiding our investment decisions. Additionally, his associates in academia and industry could be a great resource for Arrowhead and its subsidiaries."

Among his other honors, Dr. Tombrello is a fellow of the American Physical Society. His research has primarily focused on applications of nuclear and ion beam physics to problems in materials science, geochemistry, and technology.

Source: Arrowhead Research Corporation

[Scar]

Ist halt ne langfristige Anlage. Dennoch hätte ich mir nicht gedacht, daß es nochmal so weit runter geht

[Colophonius]

Na immerhin, es besteht Hoffnung, dass die Pressearbeit von Arrowhead jetzt deutlich besser werden könnte:

Press Release Source: Arrowhead Research Corporation

Lovy to Join Arrowhead Team as Communications Director
Thursday August 25, 7:00 am ET

PASADENA, Calif.--(BUSINESS WIRE)--Aug. 25, 2005--Arrowhead Research Corporation (Nasdaq:ARWR - News) announced today that Howard Lovy, a journalist who specializes in reporting nanotech business developments and promoting public understanding of nanotechnology, has joined its team as Director of Communications. Lovy was among the founding editors of Small Times Media, the first trade magazine and website covering nanotechnology. During the past year, he has contributed analyses to the Forbes/Wolfe Nanotech Report; written white papers and reports for NanoMarkets; and covered nanotech issues for the Wall Street Journal, Wired News, Salon.com, and other publications.

"Arrowhead has kept a relatively low profile, but now we`re ready to tell the world about our innovative way of guiding the best nanotech research toward commercialization," said R. Bruce Stewart, Arrowhead`s President. "Howard will play an important role in our strategy to raise our public profile."

Stewart added: "Howard effectively communicates the simplicity and elegance of nanotech solutions. He was a pioneer at Small Times because he was among the first to set the tone and style for coverage of nanotechnology as a business."

Lovy said that Arrowhead is an ideal place for him to continue his mission of informing the general public about nanotech. "Arrowhead`s strategy of funding the most innovative research at some of the country`s top universities, and seeing them through to commercialization, appeals to me as a writer because this is where the real action is in nanotech. And Arrowhead puts me right on the front lines and allows me to be first to report some amazing new discoveries."

Lovy`s popular blog, Howard Lovy`s NanoBot (http://nanobot.blogspot.com), introduced new audiences to nanotech when it launched in late 2003 and quickly became a major source of nanotech news and commentary followed by major media outlets and the growing blogosphere. His commentaries helped set the agenda for discourse on the business, technological, ethical, and environmental implications of nanotechnology. They also earned him the 2004 Communication Award from the Foresight Nanotech Institute, a nanotechnology think tank.

Lovy is a 20-year veteran of the news business and worked his way up through small weeklies to mid-sized dailies, to a major metropolitan paper and then global news organizations. Before joining Small Times in 2001, Lovy was managing editor for the Jewish Telegraphic Agency in New York, which reports on Mideast and Jewish issues for publications worldwide, and spent four years at The Detroit News editing stories, designing pages, and writing features and opinion pieces.


Source: Arrowhead Research Corporation

[Scar]

stimmt, das stimmt sehr zuversichtlich.
Die Aktie ist total eingeschlafen.

Nanotechnologie gehört jedoch die Zukunft. Früher oder später wird der Titel wieder entdeckt.
Jetzt kann man noch gemütlich einsammeln


Arrowhead has kept a relatively low profile, but now we`re ready to tell the world about our innovative way of guiding the best nanotech research toward commercialization," said R. Bruce Stewart, Arrowhead`s President. " Howard will play an important role in our strategy to raise our public profile."

[Paepstin]

[Paepstin]

Wonach sieht das aus? Was meint ihr?

Päpstin

[Colophonius]

Nachrichtenfluss: besser als nichts
Kurspotenzial: ???
Gruß: Colophonius

Press Release Source: Arrowhead Research Corporation

Arrowhead Appoints Virginia Dadey as Vice President, Investor Relations
Wednesday September 14, 7:00 am ET

PASADENA, Calif.--(BUSINESS WIRE)--Sept. 14, 2005--Arrowhead Research Corporation (Nasdaq:ARWR - News) today announced the appointment of Virginia Dadey as its Vice President, Investor Relations. Ms. Dadey has fifteen years of experience in financial markets as an investment specialist and will function as Arrowhead`s nanotech investor point person. Ms. Dadey will be based in New York City, where she will call on her years of experience in institutional sales to build Arrowhead`s shareholder base and to improve shareholder liquidity.

"Arrowhead is very fortunate to attract a Vice President with Virginia`s particular combination of skills," said R. Bruce Stewart, Arrowhead`s President. "She has a successful track record in nanotech deal-making, can call on a wide network of domestic and international analysts and fund managers, plus she can speak with authority about nanotechnology as an investment."

"I can`t think of anybody better qualified to present Arrowhead`s unique nanotech business model to the investment community."

Dadey, who previously worked for the Maxim Group as Senior Vice President for institutional sales, praised Arrowhead`s "extremely compelling" business model. "Arrowhead is an innovator in developing and executing in the nanotech field."

"I believe this business sector has a bright future. I am very excited about joining the Arrowhead team which has been able to bridge the gap between the laboratory, where full research can be done, and the public markets without having to go through the large costs associated with the traditional venture capital model," Dadey said.

Dadey worked for the Maxim Group and its predecessor company, Investec, since 2001. Prior to working for Maxim Group, she was a vice president at Gruntal & Co. from 1996 to 2001. She received her B.S. from Purdue University.

[Colophonius]

Also für diejenigen die`s interessiert:
Press Release Source: Wall Street Network

AWBV, AIRN and ARWR Update the Investment Community in Exclusive Interviews With WallSt.net
Tuesday September 27, 7:00 am ET

[...]
On September 21, Bruce Stewart, President of Arrowhead Research Corp. (Nasdaq: ARWR - News) updated the investment community in an all-new, exclusive interview with Wall Street Network. Interview highlights include detailed discussions on the following topics:


* recent Phase I SBIR grant
* overview of the Company`s subsidiaries
* recent additions to the Company`s management team and advisory board
* why the Company is an attractive nanotech investment
* timeline for revenue breakout
* licensing revenue vs. sales revenue
* upcoming strategic and financial milestones

To hear the interviews in their entirety, visit www.wallst.net . The interviews can be accessed by locating the respective company`s ticker symbol under the appropriate exchange on the left-hand column of the homepage, or by entering the respective company`s ticker symbol in the Audio Search window.

About Wall Street Network

Wall Street Network is owned and licensed by Wall Street Direct, Inc. All material herein was prepared by Digital Wall Street, Inc., a multimedia provider of original, insightful commentary and news from North America`s leading publicly traded companies giving a direct link to the management of today`s fastest-growing companies through encompassing executive interviews and sector seminars. Digital Wall Street, Inc. has received four million five hundred thousand restricted shares of AWBV from the company for media and advertising services. For a complete list of our business relationships, visit www.wallst.net/disclaimer.asp .


Contact:
Nick Iyer
Digital Wall Street, Inc.
800-4-WALL-ST




--------------------------------------------------------------------------------
Source: Wall Street Network

[Colophonius]

Noch mehr Nachrichten ...

Press Release Source: Arrowhead Research Corp.

Newly Published Results Demonstrate Potential of Arrowhead Subsidiary`s Technology as a New Tool in Fight against Cancer
Tuesday October 4, 7:00 am ET

PASADENA, Calif.--(BUSINESS WIRE)--Oct. 4, 2005--A leading cancer research journal has published animal studies showing that technology being developed by a subsidiary of Arrowhead Research Corp. (Nasdaq:ARWR - News) is effective in treating metastatic cancer in mice.

The results, published in the October issue of Cancer Research, demonstrate that Calando Pharmaceuticals` proprietary delivery technology can deliver short interfering RNA ("siRNA") to targeted cancer cells and inhibit tumor growth in mice by silencing the target gene. In addition to serving as a potentially powerful new tool in the fight against a wide range of cancers, Calando`s delivery system might also be used to treat a number of other diseases.

"Although the discovery of the siRNA mechanism has been heralded as a major breakthrough, using siRNA therapeutics to attack diseases and conditions that can only be treated systemically in an effective way has been problematic," said R. Bruce Stewart, President of Arrowhead. "Many diseases, including many forms of cancer, are caused by genes gone haywire throughout the body, not just in one discreet location. The ability to shut down problem genes selectively with siRNA throughout the body could provide a means to treat a variety of human diseases. These results demonstrate Calando`s potential to unleash RNAi as a powerful new class of therapeutics."

As described in Cancer Research, Caltech and Children`s Hospital Los Angeles investigators using Calando`s delivery technology performed experiments on a mouse model of Ewing`s sarcoma, a deadly form of metastatic cancer. One group of mice received a targeted formulation of siRNA and Calando`s proprietary delivery technology and other control groups received either no treatment, or various combinations of correct and incorrect siRNA sequences, with and without Calando`s proprietary delivery technology and tumor targeting ligands. The data show that only the targeted formulation of the correct siRNA sequence and Calando`s delivery technology provided any anti-tumor efficacy. Additionally, the data demonstrate that Calando`s technology does not result in physiological abnormalities or produce an immune response.

"The results from the Caltech-CHLA collaboration conclusively show sequence-specific anti-tumor effects and the molecular targeting to and within tumor cells by the delivered siRNAs," said Dr. Mark Davis, professor of Chemical Engineering at Caltech and founder of Calando. "This study shows that the polymer system can deliver siRNA therapeutics by a route of administration and at a dose amenable to use in humans."

Insert Therapeutics, Inc., another majority-owned subsidiary of Arrowhead Research, is expecting to begin human clinical trials early next year with a conjugate of Cyclosert(TM), a sister polymeric drug delivery technology developed in the labs of Dr. Davis at Caltech, with the small molecule anti-cancer compound camptothecin.

"In light of these results and our experience working with these nanomaterials at Insert, we expect a quick path to human clinical trials for Calando," Mr. Stewart said.

For more information on Calando and its technology, visit Calando`s website at www.calandopharma.com

Contact:
Arrowhead Research Corp.
R. Bruce Stewart, 626-792-5549
[e-mail]

Source: Arrowhead Research Corp.

Gruß Colophonius

[Colophonius]

Noch`ne Meldung...

Press Release Source: Arrowhead Research Corporation

Arrowhead Accelerates Capital Contribution to Insert Therapeutics as Nanotech Cancer Drug Heads toward Human Clinical Trials
Tuesday October 11, 7:00 am ET

PASADENA, Calif.--(BUSINESS WIRE)--Oct. 11, 2005--Arrowhead Research Corp. (Nasdaq:ARWR - News), a diversified nanotechnology company providing the missing link between lab and marketplace, has accelerated its investment of an additional $3 million to majority-owned subsidiary Insert Therapeutics, Inc.

Insert`s lead anti-cancer drug, IT-101, has achieved complete remission of non-small cell lung cancer and Ewing`s sarcoma, and significant knockdown of other tumor types in preclinical results in mouse xenografts, showing promise across a wide range of cancers. The company is currently preparing to enter IT-101 into human clinical trials at the City of Hope Comprehensive Cancer Center in Duarte, Calif.

"We have continued confidence in the power of Insert`s technology," said R. Bruce Stewart, president of Arrowhead. "This contribution satisfies our funding obligation and solidifies our 68.5 percent ownership in this subsidiary."

Insert Therapeutics controls a portfolio of U.S. and foreign issued patents and pending applications covering therapeutics based on linear cyclodextrin-containing polymers, which comprises Insert`s Cyclosert(TM) family of drug delivery polymers. IT-101 is a combination of Insert`s proprietary Cyclosert platform and the potent anti-cancer compound camptothecin. Camptothecin has never been approved for use in humans due to its insolubility, toxicity, instability in human blood serum and poor pharmacokinetics, but approved analogues of the drug, irinotecan and topotecan, have demonstrated $1 billion in reported annual sales worldwide. In the mouse xenograft studies against a variety of cancer types, camptothecin enhanced by conjugation with Cyclosert proved to be more effective at lower doses compared to irinotecan.

Cyclosert was invented in the Caltech lab of chemical engineering professor and Insert founder Dr. Mark Davis, who used "molecular design" to create Cyclosert. This methodology involves the design and construction of functional materials using molecular building blocks.

For more information about Cyclosert and Insert`s preclinical results, visit Insert`s website at www.insertt.com.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) is a diversified nanotechnology company structured to commercialize products expected to have revolutionary impacts on a variety of industries, including materials, electronics, life sciences, and energy.

There are three strategic components to Arrowhead`s business model:

Outsourced R&D Program: Arrowhead identifies patented or patent-pending technologies at universities or government labs and funds additional development of those technologies in exchange for exclusive rights to commercialize the resulting prototypes. Leveraging the resources and infrastructure of these institutions provides Arrowhead with a highly cost-effective development pipeline. Currently, Arrowhead is supporting efforts in stem cell technology, and nanosensors at the California Institute of Technology and Stanford University.
Commercialization Program: After prototypes have been sufficiently developed in the laboratories, Arrowhead forms or acquires majority-owned subsidiaries to commercialize the technology and provides the subsidiaries with strategic, managerial, and operational support. At present, Arrowhead owns majority interest in subsidiaries commercializing diverse technologies, including anti-cancer drugs, RNAi therapeutics, and compound semiconductor materials.
The Patent Toolbox: Arrowhead has acquired or exclusively licensed patents and patent applications covering a broad range of nanotechnology. The Company is actively seeking to add to this intellectual property portfolio.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statement on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:
Arrowhead Research Corporation
R. Bruce Stewart, 626-792-5549
[e-mail]

Source: Arrowhead Research Corporation

[Colophonius]

Und noch eine Empfehlung (von Motley Fool):

A TINY Alternative in Nanotech
By Jack Uldrich
October 14, 2005

Until recently, investors looking for a "pure play" investment in the field of nanotechnology had one choice: Harris & Harris (Nasdaq: TINY) -- a publicly traded venture capital firm that owns small equity stakes in more than a dozen privately held nanotechnology start-up companies. Another company, however, has recently begun making some noise, and investors interested in nanotechnology are encouraged to pay it some attention. That company is Arrowhead Research (Nasdaq: ARWR). It`s headed by industry veteran R. Bruce Stewart, who founded Acacia Research, which brought Acacia Technologies (Nasdaq: ACTG) and CombiMatrix to market.

Arrowhead, like Harris & Harris, focuses almost exclusively on nanotechnology, but its approach is quite distinct from TINY`s and carries with it the potential for greater rewards as well as greater risks.

Arrowhead invests in promising nanotechnology research at leading universities -- primarily the California Institute of Technology at this time -- and, in exchange for the right to license certain intellectual property, will seek to translate that nanoscience research into real businesses.

Few knowledgeable investors question whether there is promising nanotech-related research taking place in university labs across America. This is, in part, thanks to Uncle Sam`s willingness to generously underwrite the field to the tune of almost $1 billion a year. There is disagreement, though, over the issue of whether much of this research is yet ready for the commercial marketplace. A number of promising nanotech companies have set out for commercial gold in years past only to end up shipwrecked on the cruel, unforgiving shoals of today`s hypercompetitive economy.

Arrowhead makes strategic investments at the university level. But rather than rush that technology to the market, it instead allows it to cook a little longer in the labs. When the technology is more mature or a viable product is ready to generate revenues, the company`s seasoned management team will either create a market-driven subsidiary, license the intellectual property, sell its interest to a larger company, or guide it to an IPO.

This strategy allows Arrowhead to snatch up valuable intellectual property long before any venture capital firm or large corporation would consider investing. In this sense, Arrowhead`s approach fills a much-needed gap between basic research (in which the private sector is loath to invest) and the venture capital market, which often extracts an unusually high price in return for its investment.

The risk of Arrowhead`s strategy is, of course, that the basic research it`s buying is still "basic." No one knows for sure whether it will ever amount to anything. The flipside is that because of its early entry investment, Arrowhead -- unlike Harris & Harris and other venture capital firms -- ends up owning a significantly larger percentage of its subsidiary companies. This not only gives Arrowhead`s management a much greater claim of any future profits, but it also ensures a higher degree of managerial control. Of the four subsidiaries it has created, Arrowhead owns more than 50 percent of each.

To date, management appears to be highly selective with its investments. The company claims it is interested only in technology or products that can generate between $300 million and $1 billion annually in revenues, and it typically makes no more than an initial investment in the neighborhood of $200,000 -- although that figure has grown as high as $2 million-$5 million in a few select instances.

Currently, Arrowhead has four subsidiaries. The first is Insert Therapeutics, which is developing a drug-delivery platform that uses "molecular design" -- technology that puts every atom and molecule exactly where it needs to go in order to achieve the best result. So far, Insert`s leading drug platform has shown excellent promise in animal trials in transporting cancer-fighting agents to its target with high precision and low toxicity. The company is preparing to enter its lead anti-cancer drug, IT-101, into human clinical trials in early 2006. Arrowhead has invested $5 million in the company and owns 68.5% of its shares.

The second subsidiary Arrowhead has created is Calando Pharmaceuticals, of which it has invested $2 million and owns 52%. Calando is another nanotech-related start-up and is developing a proprietary technology that can deliver short-interfering RNA (siRNA) to target cancer cells and can inhibit tumor growth by silencing the target gene. The company`s technology has also been demonstrated as being effective in animal trials and is expected to begin human trials sometime in 2006.

Aonex is Arrowhead`s third subsidiary, and it is seeking to create semiconducting nanoparticles for use in everything from LED lighting to thin, flexible solar cells. The areas of flexible solar cells and LEDs are both ripe with promise -- and I am bullish on nanotechnology`s playing an integral role in their respective development -- but here, too, Aonex faces an uphill battle. GE, Philips, and Siemens (among others) are also placing big bets on these fields.

The final subsidiary is called NanoPolaris. It is an intellectual property platform covering carbon nanotube technologies. Little more is known about this "platform" at this time, but company officials promise that more information is coming soon.

Each subsidiary has some promise. However, the field of nanotechnology is now so vast that each faces significant competition from Fortune 500 companies and private start-ups alike. For instance, Insert Therapeutics, whose most promising platform involves the targeting of a variety of cancers, faces competition from any number of companies, including GlaxoSmithKline (NYSE: GSK) and pSivida (Nasdaq: PSDV). Both are further along in their clinical trial processes, and if either is successful, Insert`s prospects will wither.

The same is true of Calando. Several public companies, including Alnylam (Nasdaq: ALNY) and Sirna Therapeutics (Nasdaq: RNAI), are aggressively pursuing the development of RNA interference therapeutics.

Lastly, anyone who has followed the field of nanotechnology knows that carbon nanotubes are among its most promising materials. The downside is that the field also has an almost endless list of competitors -- including Japanese industrial giant NEC, which has made noise in the past year about enforcing its original carbon nanotube patent. Without knowing the details of the NanoPolaris` IP platform, it is impossible to surmise the strength of Arrowhead`s position or adequately assess its strategy. It may have the equivalent of a winning lottery ticket, or it may just be holding a lot of worthless paper.

Arrowhead has a market cap of $82 million, with $25 million cash on the balance sheet. It also has few revenues and no licensing agreements. From this perspective, then, it looks very pricey. It does, however, hold some promising intellectual property and technology. At its current burn rate, it has almost another two years before management would have to go back to investors to seek additional cash.

So does the company make for a good investment? The answer depends on your penchant for risk. If it is high, I would say yes. If it is average or low, I would recommend staying away from the stock for now. (As always, investors need to also be aware that small-cap companies this small often face great volatility).

Either way, here`s what investors should look for moving forward. First, Insert has stated that it`ll begin human trials in early 2006. Investors are encouraged to watch whether management meets this milestone. Investors should also look for the same from Calando. In both cases, the initiation of human trials doesn`t guarantee success because phase 1 drugs have historically high failure rates. But moving into clinical trials does suggest that the technology is showing promise and that it is at least on the right track.

Investors are also encouraged to look for signs of corporate partnerships for Aonex -- especially in the areas of LED lighting or flexible solar cells. Such partnerships will provide some tangible proof that its technology is being taking seriously by the big players -- which is ultimately what Aonex will need to become a commercial success.

The same can be said for Arrowhead. Technology and intellectual property, in and of itself, are nice, but they don`t pay the bills. Arrowhead`s strategy has merit, but it needs to bring real products to the commercial marketplace before it can be deemed a success.

[Scar]

schön daß sich bei arrowhead wieder was tut. bald werden die 3 € geknackt

[Colophonius]

So kann`s weitergehen
ARROWHEAD RESEARCH (NasdaqSC:ARWR) Delayed quote data

Last Trade: 3.75
Trade Time: Nov 9
Change: 0.22 (6.23%)
Prev Close: 3.53
Open: 3.57
Bid: 3.74 x 100
Ask: 3.79 x 100
1y Target Est: N/A

Day`s Range: 3.52 - 3.78
52wk Range: 1.41 - 4.94
Volume: 181,665
Avg Vol (3m): 60,778.8
Market Cap: 104.94M
P/E (ttm): N/A
EPS (ttm): -0.36
Div & Yield: N/A (N/A)

[DepotInfo]

Die 3,00 € hätten wir nun deutlich.
Wohin kann die Reise auch Sicht 3-5 Jahre noch gehen?
Oder sollte man dieser Aktie eher kurzfristig investiert sein?

Grüße Thomas

[Colophonius]

Tendenz: weiter steigend
ARROWHEAD RESEARCH (NasdaqSC:ARWR) Delayed quote data

Last Trade: 3.92
Trade Time: Nov 10
Change: 0.17 (4.53%)
Prev Close: 3.75
Open: 3.75
Bid: 3.70 x 10000
Ask: 5.71 x 200
1y Target Est: N/A

Day`s Range: 3.70 - 3.95
52wk Range: 1.41 - 4.94
Volume: 276,772
Avg Vol (3m): 61,024.2
Market Cap: 109.70M
P/E (ttm): N/A
EPS (ttm): -0.36
Div & Yield: N/A (N/A)

....höchst erfreulich, Gruß C.

[ELdoce]

Wie kann es sein, dass Arrowhead nach so positiven Nachrichten in den letzten Wochen, innerhalb kürzester Zeit schon wieder so verlieren kann?
War das alles nur heiße Luft, um den Kurs kurzfristig zu puschen?

Oder gibt es andere Gründe für die erneute Talfahrt?

ELdoce

[Colophonius]

Noch `ne Unternehmensmeldung:

Press Release Source: Arrowhead Research Corporation

Arrowhead Assembles a Carbon Nanotube Patent Portfolio Through Exclusive Licenses with Leading Universities
Thursday December 8, 7:00 am ET

PASADENA, Calif.--(BUSINESS WIRE)--Dec. 8, 2005--Arrowhead Research Corporation (Nasdaq: ARWR - News), a diversified nanotechnology company, announced today that wholly owned subsidiary NanoPolaris, Inc. has assembled a portfolio of intellectual property to facilitate and enable the manufacture of nanotube-based products. NanoPolaris has exclusively licensed U.S. patents and patent applications covering technologies developed at:
California Institute of Technology
Duke University
The Pennsylvania State University
Rensselaer Polytechnic Institute
Tsinghua University at Beijing
University at Buffalo
University of California, Los Angeles
University of Toronto
"We believe carbon nanotubes will create a manufacturing revolution comparable to what plastics did for materials and silicon did for electronics," said R. Bruce Stewart, Arrowhead`s Chairman. "We are taking the lead in consolidating the fragmented patent landscape and working with manufacturers to integrate these materials into their end products."

It is widely believed that carbon nanotubes` unique electrical, mechanical and thermal properties can be harnessed to substantially improve a variety of products, including semiconductor devices, television displays, solar cells, health care products and materials used in everything from automobiles to baseball bats. Numerous companies are now seeking to develop scaled manufacturing techniques to incorporate nanotubes into their products.

"This portfolio of key patents and patent applications could be widely employed by different companies across many industries," said Leon Ekchian, President of Arrowhead. "NanoPolaris will not itself engage in manufacturing. Rather, it will provide a necessary and convenient patent toolbox to corporations planning to integrate nanotubes into their end products."

NanoPolaris will seek to generate revenue by licensing intellectual property to customers who will utilize nanotube technology in their products. NanoPolaris now controls commercialization of issued patents and patent applications claiming nanotube compositions of matter and general manufacturing techniques such as chemical vapor deposition synthesis, plasma chemical vapor deposition synthesis, purification, solubilization, separation of certain types of tubes, coating, functionalization and manipulation.

[Scar]

ja was ist denn heut los? minus 12,28 % ?
finde keine "passende" meldung

[sadawake]

Und was ist heute los? Plus 16% und ich find ebenfalls keine passende Meldung?

[sadawake]

Ich werd nicht schlau. Jetzt sogar plus 50%!!! Weiss jemand was?

[Scar]

Kann nichts finden. Auch nicht bei finance.yahoo.com
Aber ich freu mich narrisch

[Scar]

Der Anstieg ist jedenfalls bei riesigen Umsätzen 3,55 Mio !!!
von statten gegangen, was ebenfalls sehr positiv ist.

[Paepstin]

Irgendjemand scheint wohl schon ein bissi mehr zu wissen!
Ist das schöööööööööööööööööön!
Sicherlich wird eine entsprechende PR folgen und endlich geht es mal positiv ins nächste Jahr!

Fröhlichen Übergang allen Investierten!
Päpstin

[kbe]

Warum wird hier 20 % unter pari gehandelt?

[Paepstin]

Sicher weil in Deutschland verzögert und vorsichtig gehandelt wird.
Ich schätze, die meisten glauben das nicht so recht oder haben den Kurssprung in USA noch nicht gesehen.

Päpstin

[kbe]

[posting]19.457.504 von Paepstin am 30.12.05 13:53:40[/posting]Was meinst Du wie es heute weitergeht?

[Paepstin]

[posting]19.457.552 von kbe am 30.12.05 13:56:28[/posting]Damit bin ich überfragt!
Ich denke es wird von einer entsprechenden PR abhängen!

Viel Glück
Päpstin

[kbe]

[posting]19.457.645 von Paepstin am 30.12.05 14:02:56[/posting]Schaun wir mal,wies nachher weitergeht.

[Mo2]

Moin,
der link führt zu einem Artikel in Motley Fool, der Autor macht sich Gedanken über den vermeintlich grundlosen Kurssprung:

http://biz.yahoo.com/fool/051230/113596459009.html?.v=2

Gruß von Mo

[kbe]

[posting]19.464.759 von Mo2 am 30.12.05 21:39:53[/posting]Könntest du das vielleicht grob übersetzten!
Vielen Dank im vorraus.

[opelmanta3]

...nanocarbon in der chipindustrie..

ARWR
NNPP

sind die beiden die im bereich nanocarbon aktiv sind

[opelmanta3]

http://ragingbull.lycos.com/mboard/boards.cgi?board=NNPP&rea…

[sadawake]

[posting]19.464.813 von kbe am 30.12.05 21:43:05[/posting]Er schreibt, dass auf Grund der grossen Blöcke vermutlich Instis eingestiegen sind und dass Momentum-Trader die steigende Rocket nicht verpassen wollten. Er warnt aber auch davor, dass ein Titel, der ohne ersichtlichen Grund so hoch steigt, auch sehr schnell wieder zurück kommt. Das hat sich am Freitag auch bestätigt.

Trotzdem scheint er langfristig an Arrowhead zu glauben. Er hat vor rund drei Monaten schon einen Artikel über die Company geschrieben.

Die Frage ist jetzt: Drinbleiben, oder Gewinn mitnehmen und bei tieferen Kursen wieder einsteigen? Ich glaube langfristig 100% an ARWR. Zu gross ist das Patentportfolio. Aber ich überlege mir trotzdem, mindestens einen Teil des Gewinns zu realisieren.

Und was macht Ihr?

[kbe]

[posting]19.493.935 von sadawake am 01.01.06 22:33:32[/posting]Vielen Dank für deine Antwort.Da die Aktie am Freitag recht ordentlich zurückgekommen ist,denke ich eigentlich das es schon sehr bald weiter nach oben geht.Leider ohne Garantie.

[sadawake]

[posting]19.493.992 von kbe am 01.01.06 22:39:53[/posting]Vielleicht war es ein Fehler, aber ich bin heute raus aus ARWR. Ich befürchte, dass es noch weiter runter geht. Vielleicht lieg ich falsch. Aber für`s erste schaue ich lieber an der Seitenlinie zu. Ich hatte für meine Verhältnisse zu viel Geld drin, als dass ich den Verlust des Gewinnes riskieren wollte.

Aber ich beobachte den Titel fleissig weiter und steige wieder ein, wenn der Kurs Richtung 3 Dollar runter gehen sollte.

Gruss

SAD

[Scar]

Bist du gleich mit allen Aktien raus? Bei den enormen Umsätzen als die Aktie so stark gestiegen ist, erwarte ich noch viel von Arrowhead. Ansonsten wäre niemand mit so grossen Positionen eingestiegen.

[sadawake]

[posting]19.543.488 von Scar am 05.01.06 11:47:33[/posting]Ich bin im Moment mit allen raus. Im Moment! Ich habe ein scharfes Auge auf ARWR und werde wieder einsteigen. Ich hoffe zu tieferen Kursen. Das Tradingkapital und den Gewinn habe ich in CBMX (Acacia Combimatrix) parkiert, da dort das Momentum derzeit besser ist.

Gruss

SAD

[opelmanta3]

Arrowhead Added to PowerShares Lux Nanotech Exchange Traded Fund
Tuesday January 10, 7:00 am ET


PASADENA, Calif.--(BUSINESS WIRE)--Jan. 10, 2006--Arrowhead Research Corp. (Nasdaq:ARWR - News), a diversified nanotechnology company, announced today that it has been selected for inclusion in the Powershares Lux Nanotech Portfolio (AMEX:PXN - News). The PowerShares exchange traded fund (ETF) is based on the Lux Nanotech Index(TM) and is intended to track a group of leading publicly-traded companies involved in developing and manufacturing nanotechnology.

"The Lux Nanotech Index aims to be comprehensive for nanotech specialists, including all firms that meet our eligibility criteria for market valuation, trading volume, and listing on a major U.S. exchange. Arrowhead now meets these criteria," stated Matthew M. Nordan, co-chair of the Index selection committee, in the firm`s press release.

"We are pleased to be included among this exclusive list of companies developing nanotechnology and that, of the 26 companies included on the Index, Arrowhead currently has the highest weighting based upon its recent performance," stated Dr. Leon Ekchian, President of Arrowhead.

About ETFs

Exchange-traded funds (ETFs) are baskets of securities designed to replicate the performance of a stock or bond index (e.g., Dow Jones Industrial Average, S&P 500). ETFs are listed on an exchange and can be traded intra-day at a price set by the market. ETFs are designed to add the flexibility, ease, and liquidity of stock trading to the benefits of traditional index fund investing.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) is a diversified nanotechnology company structured to commercialize products expected to have revolutionary impacts on a variety of industries, including materials, electronics, life sciences, and energy.

There are three strategic components to Arrowhead`s business model:

Outsourced R&D Program: Arrowhead identifies patented or patent-pending technologies at universities or government labs and funds additional development of those technologies in exchange for exclusive rights to commercialize the resulting prototypes. Leveraging the resources and infrastructure of these institutions provides Arrowhead with a highly cost-effective development pipeline. Currently, Arrowhead is supporting efforts in stem cell technology, and nanosensors at the California Institute of Technology and Stanford University.
Commercialization Program: After prototypes have been sufficiently developed in the laboratories, Arrowhead forms or acquires majority-owned subsidiaries to commercialize the technology and provides the subsidiaries with strategic, managerial, and operational support. At present, Arrowhead owns majority interest in subsidiaries commercializing diverse technologies, including anti-cancer drugs, RNAi therapeutics, compound semiconductor materials and carbon nanotube technologies.
The Patent Toolbox: Arrowhead has acquired or exclusively licensed patents and patent applications covering a broad range of nanotechnology. The Company is actively seeking to add to this intellectual property portfolio.

[opelmanta3]

Arrowhead Announces $19.6 Million Investment by York Capital Management and Knott Partners
Friday January 13, 7:00 am ET


PASADENA, Calif.--(BUSINESS WIRE)--Jan. 13, 2006--Arrowhead Research Corporation, (NASDAQ: ARWR - News) a diversified nanotechnology company, today announced a definitive agreement to sell 5,590,000 shares of restricted common stock to York Capital Management and Knott Partners, LP. This infusion of capital is expected to accelerate Arrowhead`s growth and strengthen its strategic position within the emerging field of nanotechnology.
ADVERTISEMENT


"We think Arrowhead`s innovative and scalable business model will position it well in this growth industry. We are delighted to partner with Bruce, Leon and the Arrowhead team, helping them to accelerate their plans for investment and growth," stated Alexander Klabin, Senior Vice President of York Capital. John Schneller of Knott Partners, an existing shareholder, added, "We are excited to increase our ownership position to approximately 12.50% from 9.50% in this promising emerging growth company."

"We are extremely pleased to partner with well-established institutions of this caliber," stated Leon Ekchian, President of Arrowhead. "This capital infusion enables Arrowhead to expand its existing subsidiaries and make additional strategic investments and acquisitions, as appropriate."

Under the terms of the deal, York will purchase 4,161,429 shares of restricted common stock and Knott will purchase 1,428,571 shares of restricted common stock at $3.50 per share. Additionally, York and Knott will receive, in the aggregate, warrants to purchase an additional 1,397,500 shares of restricted common stock at $5.04 per share. The agreement is subject to final approval of the listing of the shares by NASDAQ.

[mystreet]

Sehr schöner Chart - Insider haben im Dezember gekauft.

[ELdoce]

Wunderschönes Chartbild!
Aber gibt es auch News, die diesen Anstieg rechtfertigen?

[Scar]

wirklich schön

[Scar]

die Aktie hat sich in wenigen Monaten verdoppelt und ein nicht einzuschätzendes Potential für die Zukunft. Die Patente im Nanotechbereich sind sicherlich viel mehr Wert als man derzeit erahnen kann. Doch keiner schreibt zu diesem Wert. Da bin ich ja mal gespannt was passiert, wenn die Aktie öfters empfohlen wird.

[NOBODY_III]

09.03.2006 08:20

PRESSEMITTEILUNG

Nanostart AG veräußert zwei US-Beteiligungen

Frankfurt am Main - Die Nanostart AG hat sich von zwei börsennotierten US-Beteiligungen getrennt. Das Unternehmen hat seine Anteile an der Arrowhead Research, Corp. aus Pasadena sowie an der Integral Vision, Inc. aus Farmington Hills gewinnbringend veräußert. Mit diesen Verkäufen konnte die Frankfurter Nanotechnologie-Beteiligungsgesellschaft insgesamt Gewinne im dreistelligen Prozentbereich erwirtschaften.

Die Nanostart AG beteiligte sich bereits in den ersten Monaten nach ihrer Gründung an Arrowhead Research und Integral Vision. Die Erlöse der Veräußerungen werden hauptsächlich in neue, nicht-börsennotierte Nanotechnologie-Unternehmen in Europa und den USA investiert.

Über die Nanostart AG: Die Nanostart AG ist eine Nanotechnologie-Beteiligungsgesellschaft mit Sitz in Frankfurt am Main. Das Unternehmen gliedert sich in zwei Tätigkeitsbereiche: Ein Schwerpunkt liegt in der Beteiligung an Nanotechnologie-Unternehmen. Der zweite Tätigkeitsschwerpunkt ist die Beratung von Unternehmen der Finanzbranche bei Investitionen im Nanotechnologie-Sektor.

Pressekontakt: Christofer Radic Public Relations Manager Nanostart AG Goethestraße 26-28 60313 Frankfurt am Main fon: [phone] fax: [phone] mail: [e-mail] internet: http://www.nanostart.de

Disclaimer: Diese Mitteilung stellt weder ein Angebot zum Verkauf noch eine Aufforderung zur Abgabe eines Angebots zum Kauf oder zur Zeichnung von Wertpapieren dar. Ein öffentliches Angebot von Wertpapieren der Nanostart AG im Zusammenhang mit der Einführung der Aktien im Teilbereich des Freiverkehrs (Open Market) der Frankfurter Wertpapierbörse, dem "Entry Standard", findet nicht statt. Diese Mitteilung stellt keinen Wertpapierprospekt dar. Diese Mitteilung und die darin enthaltenen Informationen sind nicht zur direkten oder indirekten Weitergabe in bzw. innerhalb der Vereinigten Staaten von Amerika, Kanada, Australien oder Japan bestimmt.




DGAP 09.03.2006
Sprache: Deutsch Emittent: Nanostart AG Goethestraße 26-28 60313 Frankfurt Deutschland Telefon: 069 / 2193 9611 Fax: 069 / 2193 9622 Email: [e-mail] WWW: www.nanostart.de ISIN: DE000A0B9VV6 WKN: A0B9VV Indizes: Börsen: Freiverkehr in Berlin-Bremen, München, Stuttgart; Open Market (Entry Standard) in Frankfurt

Ende der Mitteilung DGAP News-Service



(END) Dow Jones Newswires

March 09, 2006 02:20 ET (07:20 GMT)

[Scar]

Die Aktie steigt und steigt und keiner schreibt was dazu.
Ich konnte keinen Grund für den steten Anstieg finden. Vielleicht liegt es nur am intakten Aufwärtstrend (Chart)

[schlitzie]

auf 52 wochen Hoch

[schlitzie]

http://www.finanznachrichten.de/nachrichten-2006-04/artikel-…

[schlitzie]

Eine für alle
Hinter Arrowhead Research verbirgt sich ein Basket aus interessanten Nanotechs. Für Anleger, die sich im Nano-Dschungel noch nicht besonders gut auskennen, genau das Richtige.

Bei der Nanotechnologie handelt es sich nicht - wie so oft fälschlicherweise behauptet - um eine Branche. Auf atomarer und molekularer Ebene verwischen die Grenzen zwischen den einzelnen Naturwissenschaften, so dass die Nanotechnologie schließlich in nahezu jeder Branche ihr Potenzial unter Beweis stellen kann. Anleger stehen somit oftmals vor der Qual der Wahl, wenn es um die Auswahl interessanter Nano-Werte geht. Mit Arrowhead Research bekommt man fast alles auf einmal.

Drei lukrative Säulen
Das US-amerikanische Unternehmen hat ein clever durchdachtes Geschäftsmodell, das sich auf die drei Schlüsselbereiche "Forschungsprogramme", "Tochtergesellschaften" und "Patentportfolio" stützt. Die Töchter Insert Therapeutics und Calando Pharmaceuticals sind im wachstumsstarken Nanobiotechnologie-Markt tätig. Aonex Technologies hat sich auf die Herstellung von Halbleiter-Nanomaterialien spezialisiert und mit Nanopolaris ist Arrowhead auch im Zukunftsmarkt Nanotubes bestens positioniert. Das Marktpotenzial der vier Töchter dürfte bei mehreren Milliarden Dollar liegen. Zudem besitzt Arrowhead das weltweit am besten diversifizierte Patentportfolio im Nanotechnologie-Sektor. Auch das verspricht künftige Einnahmen. Nicht zu vergessen die Vermarktungsrechte, die man für die finanzielle Unterstützung von Forschungsprogrammen auf universitärer Ebene erhalten wird.

Es geht voran
Größtenteils spielt sich bei Arrowheads Projekten noch alles auf der Forschungsebene ab. Daher schreibt das Unternehmen bis dato noch keine nennenswerte Umsätze, geschweige denn Gewinne. Allerdings kann man bereits beachtliche Erfolge vorweisen. Erst in der vergangenen Woche machte Insert Therapeutics von sich reden. Die amerikanische Gesundheitsbehörde hat dem Unternehmen grünes Licht für die klinische Phase I für Cyclosert gegeben. Dahinter verbirgt sich ein spezielles Polymer, das zunächst in der Krebsbekämpfung eingesetzt werden soll. Bereits auf dem Markt befindliche Konkurrenzprodukte spielen den jeweiligen Unternehmen jährlich rund eine Milliarde Dollar ein. Wohl nicht mehr lange, denn laut Insert soll Cyclosert weitaus besser sein - das hätten zumindest präklinische Tests ergeben.

Fazit
Arrowhead hat im Januar die vor knapp einem Jahr prognostizierte Kapitalerhöhung abgeschlossen. Dem Unternehmen flossen dabei 19,6 Millionen Dollar zu, so dass man über ausreichend finanzielle Mittel verfügt. Gemessen an der aktuellen Marktkapitalisierung von 165 Millionen Dollar ist der Wert deutlich unterbewertet, bedenkt man das riesige Potenzial der einzelnen Projekte.Arrowhead und Co befinden sich in frühen Entwicklungsphasen. Ob der enormen Wachstumsfantasie müssen Rückschläge einkalkuliert werden
Aus dem Aktonär vom 27.03.06

[schlitzie]

heute sollte die 6 dollar marke wohl entgültig geknackt werden.

[Quadra]

Arrowhead ( zu Deutsch: Pfeilspitze) wurde 2003 gegründet und konzentriert sich auf den zukunftsträchtigen Bereich der NanoBiotechnologie. der große Vorteil der NanoBiotechnologie besteht dari, dass die Nanotech-Forschung in diesem Bereich im Vergleich zu anderen Nanotech-Sektoren schon sehr weit fortgeschritten ist. anders als bei vielen anderen Nanotech-Anwendungen kommen nano-produkte hier schon zum Einsatz.

Arrowhead kauft sich als mehrheitseigentümer bei aussichtsreichen Nanotech-Unternehmen ein. So weit ist die Unternehmensstruktur wie bei anderen klassischen VC-Gesellschaften. In dem geschäftszweig "Outsourced R&D" ( zu Deutsch: ausgelagerte Forschung und Entwicklung) sucht Arrowhead an Universitätten oder in staatlichen geförderten forschungsprogrammen gezielt nach besondrs aussichtsreichen Nanotechnologien. Diese unterstütz Arrowhead dann mit Geld, damit die Uni oder die Forschungseinrichtungen ihre Arbeit weiterführen können.

Im gegenzug erhält Arrowhead die exklusiven Lizensrechte, um die Technologien oder Prototypen kommerziell zu nutzen, wenn sich die Technologie als efektiv erweisen.

Diese Konzept ist genial da, Arrowhead seine Forschung fremd einkauft, und muss man keine eigenen Forschungslabore aufbauen. Das spart Arrowhead sehr viel Kapital!!!

Derzeit fördert Arrowhead Forschungsprojekte der Hochschulen:

- California Institute of Technology
- Duke University und
- Stanford Uiversity,

drei der besten Universitäten in den USA.

Die Forschungen drehen sich um Systeme für die Entdeckung neuer Medikamentenwirkstoffe, die Stammzell-Forschung und die Nano-Elektronik. Aktuell befinden sich 4 Unternehmen in dem Beteiligungs-Portfolio von Arrowhead: Aonex, Insert Therapeutics, calando Pharmaceuticals und NanoPolaris.

Anoex forscht für die Solar-branche an hauchdünnen Beschichtungen mit Siliziumkristallen, die eine billigere Produktion von solarzellen ermöglichen sollen. NanoPolaris soll technologien im Bereich der so genanten "Nanotubes" zu einem tragfähigen geschäftsmodell wandeln. Nanotubes sind elektr. Leiter, die wesentlich leistungsstärker als herkommliche Leiterkabel sind.

Die Aushängerschilder sind aber Calandound Insert. Calando konzentriert sich innerhalb der genforschung auf effizientere Verabreichungsmethoden für siRNA-Medikamente. Erst am 3 April gab Arrowhead bekannt, die präklinische Forschung von calando mit weitern 10 Mio. US$ zu fördern.

Für schlagzeilen sorget im März die beteilingung Insert. Den Insert erhielt von der FDA grünes Licht für den start seiner Phase-I-Studien mit dem krebsmedikament IT-101.

Bei einer MK von 189 Mio. US$ wird der Wert des Unternehmens und der Beteilungen auf 179 mio.US$ taxiert.


Das Kursziel sollte für die nächsten 12 Monate : 12 US$ lauten!!!

Ich hoffe ich konnte den einen oder anderen einwenig weiterhelfen

Gruß Quadra

[mystreet]

sensationeller Trend: kontinuierlich nach oben - auch gestern an der Nasdaq wieder!!
Eigentlich müssten wir heute in Frankfurt schon bei 5,50 stehen - gem. umgerechnetem Nasdaq-Kurs!!

Und für mich das schönste daran ist: keine Extrembewegungen durch Spekulanten, sondern KONTINUITÄT !!

[mystreet]

Was kommt da auf uns zu? NEWS-Ankündigung

Arrowhead Research Corporation News
Today is May 10, 2006. All times in US Eastern Timezone.
05/05/2006 - 07:00 AM

[Mo2]

Moin!

Außer Quartalszahlen (siehe link) gibts nix neues, oder?

http://biz.yahoo.com/e/060510/arwr10-q.html

[Scar]

das hätte so schön weiter gehen können mit dem steigenden Kurs.
Schade.

[Scar]

nimmt das denn kein Ende mehr. jetzt unter 4 €

[Scar]

so jetzt kommen wir langsam beim 200 Tage Durchschnitt an. Der wird hoffentlich halten

[schlitzie]

PASADENA, Calif.--(BUSINESS WIRE)--June 14, 2006--Arrowhead Research (Nasdaq:ARWR) announced today that NanoPolaris, its wholly-owned subsidiary, acquired substantially all the assets of Unidym, a Los Angeles company that develops carbon nanotube-based electronics. Dr. George Gruener, Unidym founder and distinguished UCLA professor, will be the Chief Technical Officer of the combined company. The first product, transparent and conductive nanotube networks, could enable the next generation of flat panel displays, touch screens, light-emitting diodes, and solar cells.


Prior to this transaction, NanoPolaris had assembled exclusive commercial rights to nanotube materials and processes developed at the California Institute of Technology, University of California at Los Angeles, Duke University, Pennsylvania State University, University at Buffalo, University of Toronto, Rensselaer Polytechnic Institute, and Tsinghua University. As appropriate, NanoPolaris will continue to execute its strategy of consolidating key technologies and intellectual property in this field.

"Combining the recent product development achievements by Dr. Gruener with the NanoPolaris patent portfolio creates significant value," said R. Bruce Stewart, Arrowhead's Chairman. "We believe carbon nanomaterials represent the next technological revolution."

Existing products such as flat panel displays, touch screens, and solar cells use indium tin oxide (ITO) as the transparent electrode. ITO, however, has limitations in its performance, a dramatically increasing price, and is not optimally suited for integration into many existing and new device architectures. Unidym's carbon nanotube networks are mechanically flexible, can be deposited on lightweight plastics instead of heavy glass, and could be substantially more conductive than ITO.

"Our transparent and conductive nanotube networks are just the beginning of the transition to an electronics industry based on carbon. Expected subsequent products include nanotube thin film transistors that enable palm pilots to bend, electronic brochures to roll up, or low cost RFID tags. As one looks to the future, there is a strong possibility that carbon nanomaterials might be used to replace metal interconnects and silicon transistors," said Dr. Gruener. "Our strategy is to leverage our knowledge of these materials to develop and bring to market increasingly sophisticated electronic devices."

NanoPolaris acquired substantially all of Unidym's net assets, including its intellectual property, prototypes, and equipment, for a purchase price consisting of cash and shares of NanoPolaris common stock equal to 10% of NanoPolaris' outstanding voting stock at closing. At the closing of this acquisition, Arrowhead Research invested $3 million in NanoPolaris and committed up to $4 million of additional capital to NanoPolaris, with $2 million to be paid on the first anniversary of closing and the remaining $2 million to be paid on the second anniversary of closing.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) is a diversified nanotechnology company structured to commercialize products expected to have revolutionary impacts on a variety of industries, including electronics, life sciences, and energy.

There are three strategic components to Arrowhead's business model:

-- Outsourced R&D Program: Arrowhead identifies patented or patent-pending technologies at universities or government labs and funds additional development of those technologies in exchange for exclusive rights to commercialize the resulting prototypes. Leveraging the resources and infrastructure of these institutions provides Arrowhead with a cost-effective development pipeline. Currently, Arrowhead is supporting efforts in drug discovery tools, stem cell technology, and nanoelectronics at the California Institute of Technology, Stanford University, and Duke University, respectively.

-- Commercialization Program: After prototypes have been sufficiently developed in the laboratories, Arrowhead forms or acquires majority-owned subsidiaries to commercialize the technology and provides the subsidiaries with strategic, managerial, and operational support. By doing so, each research team is able to maintain focus on its specific technology and each management team can focus on specific markets, increasing the likelihood of successful technological development and commercialization. At present, Arrowhead owns majority interest in subsidiaries commercializing diverse technologies, including anti-cancer drugs, RNAi therapeutics, compound semiconductor materials, and nanotube technology.

-- The Patent Toolbox: Arrowhead has acquired or exclusively licensed patents and patent applications covering a broad range of nanotechnology. The Company actively adds to its intellectual property portfolio.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies; the future success of our scientific studies; our ability to successfully develop products; rapid technological change in our markets; changes in demand for our future products; legislative, regulatory, and competitive developments; and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statement on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations, and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason

mal ein kleiner Lichtblick

[Mo2]

"We believe carbon nanomaterials represent the next technological revolution." Das glaube ich auch, die Eigenschaften dieser Nano-Tubes aus Kohlenstoffmolekülen sind in der Tat unglaublich. Aber Geduld ist schon noch gefragt.

[schlitzie]

June 21, 2006 06:00 AM US Eastern Timezone
Arrowhead Research Corporation Scheduled to Be Listed on Russell Microcap Index
PASADENA, Calif.--(BUSINESS WIRE)--June 21, 2006--Arrowhead Research (NASDAQ:ARWR) announced today that it is scheduled to join the Russell Microcap(TM) Index when the Russell Investment Group reconstitutes its family of U.S. indexes on June 30th, 2006, according to a preliminary membership list posted on Friday, June 16th, 2006, on www.russell.com.


"We are very pleased with the scheduled addition of Arrowhead to the Russell Microcap Index," said R. Bruce Stewart, Chairman and CEO of Arrowhead. "We believe the selection of Arrowhead represents recognition by Russell of the significant progress of our operating companies over the last two years. Inclusion in this index will increase our visibility with investors and institutions that rely on the Russell indexes as part of their investment strategy."

Russell, a global leader in multi-manager investment services, provides investment products and services in 44 countries. Russell manages more than $167 billion in assets and advises clients worldwide representing $2.4 trillion. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $3.8 trillion in assets currently are evaluated and benchmarked against these Russell indexes.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) is a diversified nanotechnology company structured to commercialize products expected to have revolutionary impacts on a variety of industries, including electronics, life sciences and energy.

There are three strategic components to Arrowhead's business model:

-- Outsourced R&D Program: Arrowhead identifies patented or patent-pending technologies at universities or government labs and funds additional development of those technologies in exchange for exclusive rights to commercialize the resulting prototypes. Leveraging the resources and infrastructure of these institutions provides Arrowhead with a cost-effective development pipeline. Currently, Arrowhead is supporting efforts in drug discovery tools, stem cell technology and nanoelectronics at the California Institute of Technology, Stanford University and Duke University, respectively.

-- Commercialization Program: After prototypes have been sufficiently developed in the laboratories, Arrowhead forms or acquires majority-owned subsidiaries to commercialize the technology and provides the subsidiaries with strategic, managerial and operational support. By doing so, each research team is able to maintain focus on its specific technology and each management team can focus on specific markets, increasing the likelihood of successful technological development and commercialization. At present, Arrowhead owns majority interest in subsidiaries commercializing diverse technologies, including anti-cancer drugs, RNAi therapeutics, compound semiconductor materials and nanotube technology.

[schlitzie]

PASADENA, Calif.--(BUSINESS WIRE)--July 7, 2006--Arrowhead Research Corporation (Nasdaq:ARWR), announced today that its Chairman & Chief Executive Officer, R. Bruce Stewart, will present at the NanoEquity 2006 conference in Frankfurt, Germany on Tuesday, July 11. The presentation will cover the company's business model and investment strategies.


Mr. Stewart founded Arrowhead Research in 2003 to bring university innovations in nanotechnology to market and has guided its growth to the present. Arrowhead is now operating four majority-owned subsidiaries commercializing nanotechnologies in the fields of nanomedicine, nanoelectronics, and nanomaterials. In addition, Arrowhead is sponsoring nanotechnology development at the California Institute of Technology, Stanford University and Duke University. Previous to Arrowhead, Mr. Stewart's thirty year entrepreneurial career included founding Acacia Research Corporation, now comprised of Acacia Technologies (Nasdaq:ACTG) and CombiMatrix (Nasdaq:CBMX).

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) is a diversified nanotechnology company structured to commercialize products expected to have revolutionary impacts on a variety of industries, including materials, electronics, life sciences, and energy.

There are three strategic components to Arrowhead's business model:

-- Outsourced R&D Program: Arrowhead identifies patented or patent-pending technologies at universities or government labs and funds additional development of those technologies in exchange for exclusive rights to commercialize the resulting prototypes. Leveraging the resources and infrastructure of these institutions provides Arrowhead with a cost-effective development pipeline. Currently, Arrowhead is supporting efforts in drug discovery tools, stem cell technology and nanoelectronics at the California Institute of Technology, Stanford University and Duke University, respectively.

-- Commercialization Program: After prototypes have been sufficiently developed in the laboratories, Arrowhead forms or acquires majority-owned subsidiaries to commercialize the technology and provides the subsidiaries with strategic, managerial and operational support. By doing so, each research team is able to maintain focus on its specific technology and each management team can focus on specific markets, increasing the likelihood of successful technological development and commercialization. At present, Arrowhead owns majority interest in subsidiaries commercializing diverse technologies, including anti-cancer drugs, RNAi therapeutics, compound semiconductor materials and nanotube technology.

-- The Patent Toolbox: Arrowhead has acquired or exclusively licensed patents and patent applications covering a broad range of nanotechnology. The Company actively adds to its intellectual property portfolio.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason

[schlitzie]

July 19, 2006 07:00 AM US Eastern Timezone
Arrowhead Research Subsidiary, Insert Therapeutics, Treats First Patient with Nano-Engineered Anti-Cancer Therapeutic
PASADENA, Calif.--(BUSINESS WIRE)--July 19, 2006--Arrowhead Research Corporation (Nasdaq:ARWR), announced today that its majority-owned subsidiary, Insert Therapeutics, a company commercializing delivery-enhanced therapeutics using a patented class of polymeric systems, has treated its first patient in a Phase I study of IT-101, Insert's lead anti-cancer compound.


"The initiation of the clinical development phase for IT-101 is an important milestone for Insert Therapeutics. It demonstrates our commitment to bringing innovative therapies to the clinic that address significant, unmet patient needs," said Dr. Thomas Schluep, Chief Scientific Officer at Insert Therapeutics.

The study is an open-label, dose-escalation Phase I study in patients with inoperable or metastatic solid tumors and has been designed to evaluate the safety, tolerability and pharmacokinetics of IT-101. Insert expects that between 24 and 48 patients will be enrolled in the study during its course. The study is currently being conducted at The City of Hope Cancer Center (COH) in Duarte, CA, where Yun Yen, MD., Ph.D. will lead the study.

"We congratulate the team at Insert on this latest success," said R. Bruce Stewart, Arrowhead's Chairman. "While the Phase I study is underway, Insert will continue preparations for IT-101's further clinical trials and the development of its next therapeutic candidates."

Animal studies using IT-101 showed excellent anti-cancer activity, including complete remission of certain kinds of lung cancer, among others. For more information about Insert and IT-101, please visit Insert's website at www.insertt.com.

About IT-101

IT-101 is a combination of its patented polymer technology, Cyclosert(TM), and the anti-cancer compound camptothecin. Insert's proprietary Cyclosert delivery system is based on small cyclic repeating molecules of glucose called cyclodextrins. Using modified cyclodextrins as building blocks, Insert has developed an entirely new proprietary class of materials called linear cyclodextrin-containing polymers. To the company's knowledge, Cyclosert is the first nanoparticulate drug delivery platform to be designed de novo and synthesized specifically to overcome limitations in existing delivery technologies used for the systemic delivery of therapeutics. The polymers were invented at Caltech in the lab of Dr. Mark Davis, a professor in Chemical Engineering and founder of Insert, and licensed exclusively to Insert.

Cyclosert polymers have been synthesized over a broad range of molecular weights providing tunable properties for systemic drug delivery that improve localization of active drug at the target tissue. This feature of the Cyclosert technology provides great flexibility for overcoming multiple hurdles encountered in formulation and delivery.

Discovered in the 1960s, camptothecin is a naturally occurring, water-insoluble alkaloid that has established potent activity against a broad spectrum of cancer types. Although analogues of camptothecin (e.g., irinotecan and topotecan) continue to realize nearly $1 billion in worldwide sales annually, camptothecin itself has not been commercialized due to its poor solubility and unfavorable pharmacokinetics. In numerous animal studies conducted by Insert, treatment with IT-101 result in protracted anti-tumor activities that are substantially more effective than irinotecan or camptothecin administered alone.

About Insert Therapeutics, Inc.

Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), is using its proprietary, nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials -- linear cyclodextrin-containing polymers that are nontoxic and nonimmunogenic at therapeutic doses. The company is pursuing this goal through its internal research and development, and also through collaborations and partnerships with pharmaceutical and biotechnology companies.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) is a diversified nanotechnology company structured to commercialize products expected to have revolutionary impacts on a variety of industries, including materials, electronics, life sciences, and energy.

There are three strategic components to Arrowhead's business model:

-- Outsourced R&D Program: Arrowhead identifies patented or patent-pending technologies at universities or government labs and funds additional development of those technologies in exchange for exclusive rights to commercialize the resulting prototypes. Leveraging the resources and infrastructure of these institutions provides Arrowhead with a cost-effective development pipeline. Currently, Arrowhead is supporting efforts in drug discovery tools, stem cell technology and nanoelectronics at the California Institute of Technology, Stanford University and Duke University, respectively.

-- Commercialization Program: After prototypes have been sufficiently developed in the laboratories, Arrowhead forms or acquires majority-owned subsidiaries to commercialize the technology and provides the subsidiaries with strategic, managerial and operational support. By doing so, each research team is able to maintain focus on its specific technology and each management team can focus on specific markets, increasing the likelihood of successful technological development and commercialization. At present, Arrowhead owns majority interest in subsidiaries commercializing diverse technologies, including anti-cancer drugs, RNAi therapeutics, compound semiconductor materials and nanotube technology.

-- The Patent Toolbox: Arrowhead has acquired or exclusively licensed patents and patent applications covering a broad range of nanotechnology. The Company actively adds to its intellectual property portfolio.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason
Na,das geht ja mal runter wie butter.Bleibe auf jeden Fall long und werde noch mal nachkaufen

[schlitzie]

July 25, 2006 07:00 AM US Eastern Timezone
Arrowhead Research Subsidiary, NanoPolaris, Changes Name to Unidym
PASADENA, Calif.--(BUSINESS WIRE)--July 25, 2006--Arrowhead Research Corporation (Nasdaq:ARWR), announced today that its majority-owned subsidiary, NanoPolaris, has changed its name to Unidym. The company will continue to execute its strategy of building a patent portfolio related to carbon nanomaterials and commercializing new carbon-based electronic products. The company's first product is a transparent and electrically conductive nanotube film that addresses the estimated one billion dollar market opportunity to replace indium tin oxide (ITO) in a variety of applications, including touch screens, flat panel displays, and solar cells.


"Unidym has already shipped sample films," explained R. Bruce Stewart, Chairman and CEO of Arrowhead. "We changed NanoPolaris' name to Unidym to leverage the market traction that the Unidym team had achieved prior to Unidym's acquisition by NanoPolaris."

Unidym develops novel materials architectures that will further enhance the areas of electronics, optoelectronics and photovoltaics. The technology is based on films of carbon nanotubes, leading to high electrical conductivity, mechanical flexibility, transparency, and environmental resistance. Subsequent products are planned for applications that include low cost, flexible electronic devices based on carbon, such as displays that roll up or RFID tags.

Unidym is located in Los Angeles, California. For more information please visit www.unidym.com.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) is a diversified nanotechnology company structured to commercialize products expected to have revolutionary impacts on a variety of industries, including materials, electronics, life sciences, and energy.

There are three strategic components to Arrowhead's business model:

-- Outsourced R&D Program: Arrowhead identifies patented or patent-pending technologies at universities or government labs and funds additional development of those technologies in exchange for exclusive rights to commercialize the resulting prototypes. Leveraging the resources and infrastructure of these institutions provides Arrowhead with a cost-effective development pipeline. Currently, Arrowhead is supporting efforts in drug discovery tools, stem cell technology and nanoelectronics at the California Institute of Technology, Stanford University and Duke University, respectively.

-- Commercialization Program: After prototypes have been sufficiently developed in the laboratories, Arrowhead forms or acquires majority-owned subsidiaries to commercialize the technology and provides the subsidiaries with strategic, managerial and operational support. By doing so, each research team is able to maintain focus on its specific technology and each management team can focus on specific markets, increasing the likelihood of successful technological development and commercialization. At present, Arrowhead owns majority interest in subsidiaries commercializing diverse technologies, including anti-cancer drugs, RNAi therapeutics, compound semiconductor materials and nanotube technology.

-- The Patent Toolbox: Arrowhead has acquired or exclusively licensed patents and patent applications covering a broad range of nanotechnology. The Company actively adds to its intellectual property portfolio.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason

[schlitzie]

DUARTE, Calif. u. Palo Alto, Calif. -- (BUSINESS WIRE) -- Juli 26, 2006 -- Calando Pharmaceuticals Inc., eine Majorität-besessene Tochtergesellschaft von Arrowhead Research Corporation (NASDAQ:ARWR), hat Agilent Technologien (NYSE:A) vorgewählt um den aktiven siRNA Bestandteil in seinem Leitung RNAi Produkt, CALAA01 herzustellen. Calando wurde 2005 gebildet, um eigene Technologien für den therapeutischen Gebrauch von RNS-Störung oder "RNAi zu verursachen, zu entwickeln und in den Handel zu bringen." CALAA01 ist die ersten gerichteten siRNA krebsbekämpfenden therapeutischen dieses Calando Pläne, zum Phase I an den klinischen Versuchen teilzunehmen. Agilent stellt den siRNA Bestandteil von CALAA01 für neue Untersuchungsdroge (IND) - das Ermöglichen pharmakokinetisch und Giftigkeitstudien zur Verfügung, sowie GMP Produktion für die Phase I klinische Studie. "das Herstellung Verhältnis zu Agilent für CALAA01 aufzubauen ist ein Hauptmeilenstein in unserem Entwicklung timeline," sagte Calando CEO John Petrovich. "wir werden sehr mit der Tiefe der Erfahrung beeindruckt und starke Führung, welche die Agilent Mannschaft anbieten muß. Zusätzlich schätzten wir die Fähigkeit der Mannschaft, ein komplettes Paket der Entwicklung Services, einschließlich Entwicklung der analytischen Methoden, IND der stützenden Studien und der Stabilität anzubieten. Diese Attribute sind lebenswichtig wichtig in der Herstellung von Therapeutik so kompliziert wie siRNA Duplices." "wir sind sehr erfreut, von Calando vorgewählt zu werden, um Herstellung zur Verfügung zu stellen und Services für ihr Leitung RNAi Produkt IND-ermöglichend,", sagte James Powell, Generaldirektor Agilents der Nukleinsäure-Lösungen Abteilung. "Calando ist eine der führenden RNAi Therapeutikfirmen, wegen ihres Fokus auf Entwicklung und der Kommerzialisierung der gerichteten siRNA Therapeutik, die auf eigenen Technologien basiert, und wir freuen, nah zu arbeiten mit ihnen." Calando Technologie Calandos Cyclodextrin-enthaltene Polymer-Plastiken bilden die Grundlage für sein zweiteiliges siRNA Anlieferung System. Der erste Bestandteil ist ein lineares und Cyclodextrin-enthält polycation, das, wenn es mit kleiner behinderender RNS (siRNA) gemischt wird, an das anionische "Rückgrat" des siRNA bindet. Das Polymer-Plastik und das siRNA Selbst-bauen in nanoparticles ungefähr 50 nm des Durchmessers zusammen, die völlig das siRNA vor Nukleaseverminderung im Serum schützen. Das siRNA Anlieferung System ist für intravenöse Einspritzung bestimmt worden. Nach Anlieferung zur Zielzelle, bindet das zielende ligand an Membrane Empfänger auf der Zelle Oberfläche und das RNS-ENTHALTENE nanoparticle wird in die Zelle durch endocytosis genommen. Dort errichtete Chemie in die Polymer-Plastik Funktionen zum unpackage das siRNA vom Anlieferung Träger. Zusätzlich zum Zielen der Tumoren, ist das Zielen der Leberzellen auch in vivo vollendet worden. Mit anti-FAS siRNA sind Leber gerichtete Anlieferung von den Endstückadereinspritzungen in den Mäusen, Genhemmung wie das FAS zur Verfügung zu stellen, das von einer Hochdruckendstückadereinspritzung beobachtet wird, die nicht klinisch relevant ist. Über Calando Pharmazeutische Produkte Inc.. Calando Pharmaceuticals Inc., eine Majorität-besessene Tochtergesellschaft von Arrowhead Research Corporation (NASDAQ:ARWR), verwendet seine eigenen Technologien zum Design und verursacht neue, gerichtete siRNA Therapeutik. Eigene Technologien der Calando Mähdrescher in gerichteten polymerischen Anlieferung Systemen und im siRNA Design, zum von von Therapeutik zu verursachen. Die Firma übt dieses Ziel durch seine interne Forschung und Entwicklung und auch durch collaborations und Teilhaberschaften mit den pharmazeutischen und Biotechnologiefirmen aus. Zu mehr Information Besuch www.calandopharma.com. Über Agilent in den Nukleinsäuren Agilent, durch seine Nukleinsäure-Lösungen Abteilung, die in Boulder, Colo. gegründet wird, ist ein führender Versorger der flexiblen therapeutischen oligo Entwicklung Services und der Herstellung Lösungen für das biotech und die pharmazeutischen Industrien. Zusätzlich Herstellung GMP zu den therapeutischen oligo Materialien bietet Agilent auch eine Reihe schlüsselfertige Services, einschließlich Entwicklung der analytischen Methoden und der Prozesse, der Stabilität Studien, der Qualitätskontrolle und der regelnden Unterstützung an. Informationen über Agilents Nukleinsäure-Lösungen Abteilung sind auf dem Netz an www.chem.agilent.com/Scripts/Generic.ASP?lPage=50795 vorhanden. Die Nukleinsäure-Lösungen Abteilung ist ein Teil der neuen Gruppe Geschäft Agilents, die gechartert wird, um die neuen Geschäfte zu entwickeln, die mit der Wachstumstrategie der Firma gleichbleibend sind. Über Agilent Technologien Agilent Technologies Inc. (NYSE:A) ist die Premier-Maßfirma der Welt und ein Technologieführer in den Kommunikationen, in der Elektronik, in den Lebenwissenschaften und in der chemischen Analyse. Die Angestellten der Firma 20.000 dienen Kunden in mehr als 110 Ländern. Agilent hatte Reineinnahme von $5.1 Milliarde in steuerlichem Jahr 2005. Informationen über Agilent sind auf dem Netz an www.agilent.com vorhanden.

[schlitzie]

Was
top ARWR Stats Symbol Search


Time B/S Shares Price

14:53:25.126 B 100 5.3200

14:53:00.190 B 200 5.3100

14:52:00.182 B 100 5.3100

14:51:56.149 B 200 5.3000

14:51:45.617 S 100 5.3200

14:50:55.157 B 200 5.3300

14:49:54.547 B 200 5.3100

14:49:42.405 B 100 5.3000

14:48:58.078 B 300 5.3000

14:48:53.840 B 100 5.2900

14:48:39.550 B 100 5.2800

14:48:21.179 B 100 5.2700

14:45:56.092 B 100 5.2700

14:45:52.071 B 100 5.2700

14:45:20.155 B 100 5.2700

14:45:15.653 B 100 5.2700

14:44:07.093 B 100 5.2700

14:44:03.122 B 100 5.2700

14:43:08.093 B 100 5.2700

14:43:07.563 B 100 5.2700

ist denn bei den Ami´s los???sind zwar alles nur 100 order,egal hauptsache es geht richtung norden

[schlitzie]

2006--Arrowhead Research Corporation (Nasdaq:ARWR), announced today that it will begin a collaboration with Dr. Andrew Rinzler to further develop flexible electronic devices made at the University of Florida. Arrowhead will have the first option to exclusively license and commercialize the technology.


"Dr. Rinzler has made new thin film transistors using carbon nanotubes that could break open this field," said R. Bruce Stewart, CEO and Chairman of Arrowhead. "We look forward to working with him to optimize his devices and put together a plan for commercialization."

Thin film transistors (TFTs) can be used to make products such as low cost RFID (radio frequency ID) tags, flexible displays, and electronic paper. Further, unlike state of the art electronics manufacturing facilities which cost billions of dollars, flexible electronics are likely to be produced with low cost ink-jet printing technologies. According to estimates from NanoMarkets, the total market for products based on thin film transistors could reach over $20 billion by 2012.

Dr. Rinzler is a professor in the Physics Department at the University of Florida, specializing in carbon nanotube processing and devices. In addition to his novel nanotube-based transistor architecture, he also developed pure homogeneous nanotube films as transparent conductors. As a post doctoral fellow in Rick Smalley's Laboratory, Dr. Rinzler was among the early researchers to develop the field of carbon nanotubes. He was listed by Thomson ISI in the top 10 of the most cited authors in Nanotechnology for the decade 1992-2002. He is coauthor on over 65 refereed publications, with 20 patents issued and several applications in process.

Under the agreement with the University of Florida, Arrowhead will provide $647,000 over a two year period to develop optimized TFT devices and prototypes of TFT arrays.

[schlitzie]

Arrowhead Announces Issuance of Patent on Subsidiary's Key Technology
BIOWIRE2K
PASADENA, Calif.--(BUSINESS WIRE)--Aug. 16, 2006--Arrowhead Research Corporation (Nasdaq:ARWR) announced today that U.S. Patent No. 7,091,192, titled "Linear Cyclodextrin Copolymers," has been issued to the California Institute of Technology. The patent is exclusively licensed to Arrowhead's majority-owned subsidiary, Insert Therapeutics, a company commercializing delivery-enhanced therapeutics using a patented class of polymeric systems.


"Having strong patent protection is crucial to high tech companies, particularly those in the nanotech space," said R. Bruce Stewart, Arrowhead's Chairman. "Arrowhead will continue to aggressively build and protect our intellectual property rights."

This patent is the final U.S. Patent to issue from a series of three related applications covering the composition, method of preparation and methods of use of a new class of polymers for delivery of therapeutic compounds. These polymers, part of a family designated as Insert Therapeutics' proprietary Cyclosert(TM) technology platform, represent a significant advance in the use of cyclodextrins for delivery of therapeutic compounds.

Insert is currently using Cyclosert(TM) technology in its lead drug candidate, IT-101, an experimental drug being studied for the treatment of cancer in clinical trials at City of Hope Cancer Center in Duarte, Calif. IT-101 is a conjugate of one of the Cyclosert(TM) polymers and the anti-cancer small molecule drug camptothecin.

"This patent represents the final piece of the foundation for Insert's extensive portfolio of patents and patent applications relating to its Cyclosert(TM) drug delivery systems," said John Petrovich, President of Insert. "It gives us substantial intellectual property protection for IT-101 and other product candidates that we are developing internally."

Insert has also licensed Cyclosert(TM) technology to its affiliate, Calando Pharmaceuticals, which is using another of the Cyclosert(TM) family of polymers to deliver siRNA duplexes in the area of RNA interference, a novel gene-silencing technology that may lead to an entire new class of therapeutics.

The patent also covers methods for adding modifiers to the polymer/drug complex to enhance its stability in the bloodstream and to provide targeted delivery to tissues or cells of interest. Other issued and allowed patents cover various means of adding modifier components to the polymer that aid the stability of the resulting polymer-drug nanoparticles in vivo and allow for the attachment of various targeting ligands.

The claims cover polymers containing repeating units of cyclodextrin molecules and various co-monomers, linked together in a linear chain. In contrast to other approaches that graft molecules onto a polymer, Cyclosert incorporates the cyclodextrin molecules into the polymer "backbone," resulting in a consistently replicable polymer. This feature has aided in scale-up and resulted in more consistent commercial manufacture. Insert's linear cyclodextrin-containing polymers can form complexes with compounds ranging in size from small molecule drugs to nucleic acids for improved drug delivery.

When combined with small molecule drugs, the Cyclosert polymers have been shown to significantly improve the solubility, stability, toxicity, efficacy and pharmacokinetic profiles of therapeutic compounds. Further, they can be designed to be neutral, positively charged or negatively charged and can be targeted with the attachment of cell surface receptor ligands. Unlike passive drug carriers, Cyclosert polymers respond to biological mechanisms and micro-environmental conditions. This enables controlled release of their drug payload into the targeted tumor cell or other selected tissues.

For more information about Insert, please visit the website at www.insertt.com.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
Vielleicht macht das Patent,dem Kurs mal ein paar Flügel.

[schlitzie]

PASADENA, Calif. -- (BUSINESS WIRE) -- Sept.. 6, 2006 -- Calando Pharmaceuticals Inc., eine führende RNAi Therapeutikfirma und Majorität-besessene Tochtergesellschaft von Arrowhead Research Corporation (Nasdaq:ARWR), stellte heute mehr Detail auf seinem Produkt und Unternehmensziele für 2007 zur Verfügung. "wir haben beträchtlichen Fortschritt gebildet, seit wir Betriebe in mid-2005 begannen - wir stellten sehr ehrgeizige Ziele für Calando 2005 ein und 2006, zum der Grundlage für unsere Produktrohrleitung- und -zukunftteilhaberschaften zu legen,", sagte John Petrovich, Präsident und Generaldirektor von Calando. "2007, errichten wir auf dieser Grundlage, indem wir fortfahren, unser erstes experimentelles RNAi vorzurücken, das therapeutisch ist in Richtung zu den klinischen Versuchen, in den Hoffnungen des Beginnens Phase I von von Versuchen vor dem Ende des Jahres." Nach Ansicht Calando des wissenschaftlichen hauptsächlichoffiziers würde Dr. Jeremy Heidel, Calandos erstes RNAi, das therapeutisch ist, das Zum Schweigen bringen eines Gens verweisen, das in einer breiten Vielzahl der festen Tumoren impliziert wurde. "unser Erfolg in den vor-klinischen Studien, die unterschiedliche Arten der Krebszellen mit einbeziehen, versieht uns mit Optimismus über die Aussichten des Behandelns der zahlreichen Arten der Krebspatienten mit therapeutischem diesem." Therapeutischen Calandos ersten enthält ein zielendes ligand der Zelle Oberfläche Empfänger, für den auf einer breiten Vielzahl der unterschiedlichen Krebse über-ausgedrückt wird. Die Kombination eines generalisierten Genziels und ein generalisierter Zelle Oberfläche Empfänger, der ligand zielt, statten Calandos aus, das mit Eigenschaften therapeutisch ist, die es möglicherweise anwendbar für die Behandlung eines ausgedehnten Spektrums der festen Krebse bilden. Zusätzlich zum Kennzeichnen des Ausgangsgenziels für sein erstes therapeutisches, hat Calando: -- eingeordnet für Patentschutz seiner siRNA Reihenfolgen für das Genziel und genehmigte SchlüsselsiRNA Patente von den Alnylam pharmazeutischen Produkten. -- hergestellt stufenSie und Herstellung Verhältnisse für das siRNA Bestandteil und Calandos eigene Cyclodextrin-Polymer-Plastik Anlieferung System und bestellte Materialien für IND-ermöglichende Giftigkeitstudien und GMP Materialien für seinen Phase I Versuch ein. Hersteller schließen Agilent Technologien, Cambrex und SunBio mit ein. -- hergestelltes Sicherheit Profil für das komplette therapeutische, körperlich ausgeübt in den nicht menschlichen Primas. Calando plant z.Z., einen neuen Untersuchungsantrag der Droge (IND) mit der US Nahrungsmittel-und Droge-Leitung und nach Abstand der regelnden Anforderungen und des Institutionsberichts durch den klinischen Probeaufstellungsort zu stellen, Calando Hoffnungen, seinen ersten klinischen Versuch in einer führenden südlichen Kalifornien Krebsmitte vor dem Ende 2007 anzufangen. Die Firma glaubt, daß dieser klinische Versuch das erste gerichtete siRNA ist, das gegen den Krebs therapeutisch ist, zum der Klinik zu erreichen. "therapeutischen Calandos ist ein gerichtetes RNAi therapeutisches entworfenes de Novo,", sagte Professor des Dr. Mark Davis, Caltech und Calando gründenwissenschaftler. "es kombiniert synthetische Anlieferung Bestandteile mit dem Zielen der Mittel und siRNAs, die nicht chemische Änderung erfordern, die erste seines freundlichen nanoparticulate zu verursachen, das für Krebs therapeutisch ist. Das therapeutische ist ein ' intelligentes ' nanoparticle, das ausgezeichnete Sicherheit und Mangel an immunostimulatory Effekten im Nagetier und in den nicht menschlichen Primasstudien gezeigt hat. Wir werden aufgeregt zu Übergang gerichteter siRNA-gegründeter Therapeutik zur Klinik, während alle in auffangen wirkungsvollen den verwirklichen, gerichtete Anlieferung sind der heilige Gral." Calando hofft auch, einen zusätzlichen Entwicklung Anwärter zur Hälfte zweite von 2007 zu verkünden, da es fortfährt, seine Rohrleitung der RNAi Therapeutikprogramme zu erweitern. Über RNS Störung (RNAi) RNS-Störung oder RNAi, ist eine natürlich vorkommende Einheit innerhalb der Zellen für spezifische Gene selektiv zum Schweigen bringen und regulieren. Da viele Krankheiten durch die nicht angebrachte Tätigkeit der spezifischen Gene verursacht werden, könnte die Fähigkeit, Gene selektiv durch RNAi zum Schweigen zu bringen eine neue Weise zur Verfügung stellen, eine breite Strecke der menschlichen Krankheiten zu behandeln. RNAi wird durch die kleinen, double-stranded RNS-Moleküle verursacht. Eine Methode, zum von von RNAi zu aktivieren ist mit chemisch synthetisiertem kleinem behinderendem RNAs oder siRNAs, die double-stranded RNAs sind, das zu einem spezifischen Krankheit-verbundenen Gen gezielt werden. Die siRNA Moleküle werden durch die natürliche RNAi Maschinerie in den Zellen benutzt, um das in hohem Grade gerichtete Genzum Schweigen bringen zu verursachen. Über Calando Pharmazeutische Produkte Inc.. Calando Pharmaceuticals Inc., eine Majorität besessene Tochtergesellschaft von Arrowhead Research Corporation (Nasdaq:ARWR) verwendet seine eigenen Technologien in gerichteten polymerischen Anlieferung Systemen und in siRNA Design, um neue, gerichtete siRNA Therapeutik zu entwerfen und zu verursachen. Die Firma übt dieses Ziel durch seine interne Forschung und Entwicklung und auch durch collaborations und Teilhaberschaften mit den pharmazeutischen und Biotechnologiefirmen aus. Zu mehr Information Besuch www.calandopharma.com. Calando Technologie Calandos Cyclodextrin-enthaltene Polymer-Plastiken bilden die Grundlage für sein zweiteiliges siRNA Anlieferung System. Der erste Bestandteil ist ein lineares und Cyclodextrin-enthält polycation, das, wenn es mit kleiner behinderender RNS (siRNA) gemischt wird, an das anionische "Rückgrat" des siRNA bindet. Das Polymer-Plastik und das siRNA Selbst-bauen in nanoparticles ungefähr 50 nm des Durchmessers zusammen, die völlig das siRNA vor Nukleaseverminderung im Serum schützen. Das siRNA Anlieferung System ist entworfen worden, um intravenöse Einspritzung zuzulassen. Nach Anlieferung zur Zielzelle, bindet das zielende ligand an Membrane Empfänger auf der Zelle Oberfläche und das RNS-ENTHALTENE nanoparticle wird in die Zelle durch endocytosis genommen. Dort errichtete Chemie in die Polymer-Plastik Funktionen zum unpackage das siRNA vom Anlieferung Träger. Zusätzlich zum Zielen der Tumoren, ist das Zielen der Leberzellen auch in vivo vollendet worden. Vorwärts-Schauen Von von Aussagen Diese Nachrichten Freigabe enthält das Vorwärts-Schauen von von Aussagen, wie definiert im Börsengesetz von 1934 und ist abhängig von den sicheren Häfen, die darin hergestellt werden. Die Vorwärts-schauenden Aussagen, die hierin enthalten werden, schließen ein, aber werden nicht auf, die Informationen betreffend sind die vorweggenommenen Anwendungen von Calandos eigenen Technologien und sein Gebrauch in der Anlieferung des siRNA Designs begrenzt, sowie die Fähigkeit von Calando, bestimmte strategische Zielsetzungen zu treffen. Diese Vorwärts-schauenden Aussagen beziehen Gefahren und Ungewißheiten mit ein, die Erfolg Calandos beeinflussen. Solche Gefahren und Ungewißheiten schließen ein, aber werden nicht auf die Gefahren begrenzt, die mit Änderungen im RNS-Synthesemarkt verbunden sind und die Gefahren, die im Allgemeinen mit der Entwicklung Forschung und Entwicklung Calandos der Bemühungen und der gesamten strategischen Zielsetzungen der Firma verbunden sind. Vorwärts-schauend basieren Aussagen auf dem Glauben und den Annahmen von Management Calandos und auf zur Zeit verfügbaren Informationen. Calando nimmt sich keine Verantwortlichkeit auf, jede mögliche Vorwärts-schauende Aussage öffentlich zu aktualisieren oder zu verbessern. hat auch einer von euch pillemännern,ne meinung zu arrowhead??????????? vielleicht kommt ja auch mal ein Austausch von Meinungen hier zustande ??????????

[golfie2011]

He Schlitzi, ich hab ne Meinung zu Arrowhead.
Ich halte 500 von den Teilen in der Hand und freu mich schon auf die nächsten Jahre.
Die Dinger brauchen noch Zeit aber die werden der Knaller in jedem Depot.